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Abstract
This thesis investigates the role of vitamin E in protection of lipids and 
phospholipids against free radical damage in three studies on distinct patient 
groups. Levels of vitamin A, cholesterol, triglyceride and HDL-cholesteroi were 
also assessed.
The first study assesses nutritional aspects of vitamin E levels in hospital 
in-patients, patients on nutritional supplements and patients from general 
practices located in areas of differing deprivation categories. Plasma vitamin A 
levels were assessed to review this vitamin’s status as levels below 0.7 pmol/L 
may indicate inadequacy. It was expected that the vitamin E when corrected for 
lipid would be lower in the intensive care and high dependency unit patient 
groups. However this was not case as the vitamin E/cholesterol was highest in 
patients in the intensive care unit. This observation challenges the convention of 
correcting vitamin E with cholesterol or cholesterol and triglyceride when 
assessing depletion in acutely ill patients due to the effects of the acute phase 
response on the lowering of cholesterol levels. The study also Indicates no 
difference in vitamin E levels between deprivation categories 1 & 2 and 
categories 6 & 7.
The second study assesses vitamins A and E as well as cholesterol, triglyceride 
and HDL-cholesterol against cardiac troponin I (a specific marker of myocardial 
muscle damage). The findings of this study indicate no correlation between the 
vitamin E/cholesterol ratio or vitamin E and myocardial damage, as assessed by 
elevated levels of troponin I.
The third study assessed vitamins A and E as well as cholesterol and 
triglyceride in schizophrenia and tardive dyskinesia. These two groups were 
studied because lipid peroxidation and therefore vitamin E depletion may be 
associated with schizophrenia and tardive dyskinesia. In this study the vitamin 
E/cholesterol ratio showed no difference between the schizophrenic patients
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and normal controls. There was also no difference between patients with tardive 
dyskinesia and normal controls or schizophrenic controls. However in all 
schizophrenic groups vitamin E alone was significantly lower than the respective 
control groups but still well within the normal range.
The results from these studies suggest that low levels of plasma vitamin E 
are a rare finding. The concept of correcting vitamin E with lipid may be 
appropriate in the normal healthy population, out patients and the general ward 
population but this correction should not be used when assessing acutely ill 
inpatients. In these acutely ill patients levels of vitamin E should be assessed 
with indicators of acute phase response (C-reactive protein), liver function and 
lipid status.
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Introduction.
The thesis reviews the various processes involved in free radical action in 
biological process, particularly those associated with oxygen and considers 
defence mechanisms available as they apply in man. The study focuses on the 
role of vitamin E as the principle defence against free radical damage of lipids 
and plasma lipids in the cell membrane structure.
Certain nutritional and disease states can challenge these free radical 
defences. The studies of patient groups examine how this antioxidant vitamin 
responds qualitatively to such a challenge.
This thesis is based on three studies on distinct patient groups:
> Nutritional aspects of hospital in-patients, nutritionally supported 
outpatients and patients from general practices located In areas of 
differing deprivation categories.
> Patients with chest pain in the intensive care unit.
> Schizophrenic patients with or without Tardive Dyskinaesia
Each study group will be treated separately, having their own introduction 
including the role of antioxidants and lipid peroxidation relevant to the study.
The following section of the thesis will give a general outline of the 
mechanisms of free radical production, their affects on the lipid components of 
biological systems and their control by antioxidants.
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1.1 Free Radicals.
Atoms consist of a nucleus (made up of uncharged neutrons and positively 
charge protons) and negatively charged electrons, which spin around the 
nucleus in defined shells. In most biological molecules electrons exist In pairs, as 
this is the stable configuration. Given this requirement for pairing, any situation in 
which a species is generated with an unpaired electron will result in a potentially 
reactive entity known as a free radical. They can be highly reactive atoms or
molecules containing an odd number of electrons, such that one or more is
1unpaired . Free radicals can be formed in three ways (Figure 1):
a) When a covalent bond is broken if one electron from each of the shared 
pair remains with each atom, i.e. hemolytic fission occurs.
b) By the loss of a single electron from a normal molecule.
c) The addition of a single electron to a normal molecule.
Radical Formation:
a) By hemolytic fission: X : Y X + Y
b) By electron transfer:A -> A + e
c) By electron transfer: A + e A
The unpaired electron and its radical nature are conventionally indicated by a
heavy superscript dot.
Figure 1.
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Electron transfer by addition is far more common In biological systems than is 
hemolytic fission, the latter requiring high-energy input such as UV light, high 
temperatures or ionising radiation.
The most reactive free radicals in biological systems are radical derivatives of 
oxygen. A superoxide free radical anion (‘superoxide’) will be produced by the 
reduction of oxygen caused by the transfer of a single electron (Figure 2)
Suoeroxide Production:
0^ + e -4  0 /
Figure 2.
A two-electron reduction with hydrogen ion would produce hydrogen peroxide
(Figure 3).
Hvdroaen Peroxide Production:
0^ + 2e +2 H % H g O g
Figure 3.
In biological systems, hydrogen peroxide is often formed when two superoxide 
molecules react together (Figure 4).
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Hydrogen Peroxide Formation Via Superoxide Production:
20^ + 2H H^O  ^+
Figure 4.
The reaction shown in figure 4 is known as a dismutation reaction as the radical 
reactants produce non-radical products. This reaction occurs as a slow
spontaneous reaction or can be catalysed by the enzyme superoxide
2dismutase. Hydrogen peroxide is not a free radical as such but is known as ‘a 
reactive oxygen species’ (ROS). This group of ROS includes not only oxygen 
free radicals but also non-radical oxygen derivatives that are involved in oxygen 
free radical production.
Hydrogen peroxide has a tendency to break down spontaneously, 
especially In the presence of transition ions (such as iron or copper). On break
down it forms the most reactive and damaging of oxygen free radicals, the
3hydroxyl radical and b 
biochemistry (Figure 5).
ecause of this it is an important compound in radical
Hydrogen Peroxide Break Down:
H O  + Fe^" OH* + 0H '+  Fe^ "" 2 2
Figure 5.
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The reaction shown in figure 5 is often referred to as the iron catalysed Haber- 
Weiss reaction. A non-catalysed form of this reaction can occur when the 
superoxide radical reacts directly with the hydrogen peroxide. However this 
spontaneous reaction is less likely to occur in biological systems because of the 
low steady state concentrations of the reactants. The iron-catalysed reaction can 
still be considered to be dependent on superoxide as both the source of 
hydrogen peroxide (Figure 4) and as the reductant of the transition metal ions 
(Figure 6).
Reduction of Transition Metal Ions bv Suoeroxide:
3+ 2++ Fe —> Fe + 0^
2+ +
0 , + Cu Cu + Og
Figure 6.
2+ +The ferrous (Fe ) and cuprous (Cu ) ions are much more reactive with hydrogen
peroxide than their oxidised counterparts. The autoxidation of these reduced
transition metals can also generate superoxide (Figure 7).
Autoxidation of Reduced Transition Metals
2+ 3+Fe + Og —> Fe +
+  2+Cu + Og —^ Cu +
Figure 7.
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These reversible redox reactions between the transition metai ions and oxygen
4are extremely important in the promotion of free radical reactions .
1.2 Common Sources of Free Radicals
There are a limited number of free radical species that appear to play a 
central role in biological and pathological processes. These radicals are 
important because they possess redox potentials such that they aggressively 
react with other cellular molecules or, as more commonly occurs, they participate 
in chemical reactions that subsequently yield highly reactive free radical species.
Common sources of biologically important free radicals include:
1: Mitochondrial Electron Transport.
2: Polymorphonuclear leukocytes - NAD PH oxidase.
3: Prostaglandin synthesis.
4: Oxyhaemoglobin to methaemoglobin reaction.
5: Xanthine oxidase.
6: Reactions involving transition metals - Haber-Weiss.
7: Reactions of toxins, e.g., paracetamol, carbon tetrachloride, paraquat, 
ethanol.
8: Radiation injury.
Under normal circumstances, the major source of free radicals in cells is 
electron ‘leakage’ from electron transport chains generating superoxide. Other 
enzymes can also produce superoxide or hydrogen peroxide, such as the range 
of flavin oxidases located in peroxisomes. Other potential sources of superoxide 
in animal cells include ascorbic acid (Vitamin C), thiols (e.g. glutathione.
Page 15
cysteine), adrenaline and flavin co-enzymes. These pro-oxidation reactions can
be greatly enhanced by the involvement of transition metal ions such as iron.
The major biological process leading to oxygen derived generation is
electron transport associated with the mitochondrial and endoplasmic reticulum
5 6 7membranes ’ ’ . Normally, the reductive conversion of oxygen to H^O by the 
oxidase process requires the sequential transfer of electrons, which is 
accompanied by free radical formation. Mitochondria provide a high rate of 
production when the inner membrane associated respiratory chain carriers are in
8,9the reduced state and Adenosine Diphosphate (ADP) is low . The current
understanding is that the sequence ubiquinone to cytochrome b is the most likely
"• 10site of Og generation . The intramitochondrial steady-state concentration of
-12 10superoxide has been estimated to be 8 x 10 M . Most of the produced by 
mitochondria is converted to by mitochondrial superoxide dismutase; 
although some of this can diffuse into the cytosol. To minimise the amount 
of HgOg leakage into the surrounding cytoplasm, it would be biologically
advantageous for the cell to neutralise within the mitochondrial compartment 
as much as possible by superoxide dismutase.
The microsomes of the endoplasmic reticulum and nuclear membranes 
also contain electron transport systems and cytochrome P-450 and b ,^ which
may produce free radicals. Cytochrome P-450 is the terminal component of
electron transport chains found in adrenal mitochondria and liver microsomes. 
Cytochrome b  ^appears to be a specific electron carrier for the desaturation of
fatty acids to cis-unsaturated fatty acids. The role of cytochrome P-450 is 
hydroxylation rather than oxidative phosphorylation. During NAD PH oxidation.
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liver microsomes generate and H^O ,^ both in the absence and presence of
11 12 13mixed function oxidase substrates ’ . Changes in the isoenzyme status of
NADPH-cytochrome P-450 reductase may influence the potential to generate
14free radicals .
Numerous catalytic cytosolic enzymes also contribute to , OH and 
particularly H^O  ^generation. Various oxidases, localised throughout the cells,
17are present in high concentrations in peroxisomes of the liver . Peroxisomes
contain high amounts of catalase, which can neutralise the potentially damaging 
effects of HgO .^ The action of catalase is fundamentally the same as that
4employed by peroxidase (although 10 times faster than peroxidase) in that it 
catalyses the breakdown of hydrogen peroxide to oxygen and water. This will be 
returned to later.
Other major non-membrane related sites of free radical generation are
found in cells engaged in phagocytic activity. A respiratory burst during
phagocytic activity generates reactive oxygen radicals essential for the host’s
defence against invading microbes. During phagocytosis, a membrane-bound 
oxidase is activated in these cells, leading to an increased uptake and
production of and H^O .^ It is generally believed that the activated phagocytic
cells generate substantial amounts of H^O  ^and that this species is mainly
16,17responsible for the cytotoxic potential seen in localised tissue inflammation 
In addition to H^O  ^generation OH may also be generated during phagocytosis.
Hydroxyl radical generation could arise from the Haber-Weiss reaction or the
•  2+iron catalysing Fenton reaction in which H^O  ^is reduced to OH by Fe . 
Xanthine oxidase is another well-known source of O  ^ generation as
18,19indicated by its ability to reduce cytochrome c . The wide distribution of this
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enzyme suggests a potentially important role in pathogenic conditions such as
ischaemic injury in a wide variety of organs including myocardium and the
20intestinal mucosa . Under ischaemic conditions cellular ATP levels decrease, 
leading to a rise in cellular calcium with activation of a protease responsible for 
the conversion xanthine dehydrogenase to xanthine oxidase. Upon reperfusion
and reoxygenation, xanthine oxidase uses oxygen to metabolise hypoxanthine to
- •  21uric acid with the production of O
1.2.1 Superoxide Radical
Superoxide is commonly formed from oxygen and a redox cycling
22 23molecule (Figure 9). It is a weak oxidant and a potent reductant with a half-
24 .life in the millisecond range It is unlikely to cause significant cellular injury on 
its own, as it is a weak oxidant. Once formed the superoxide radical may have
23,25one of several fates. It may react with nucleophilic thiol groups and may thus 
either predispose the cell to further oxidative stress by depleting 
glutathione (GSH), or react with thiol groups on enzymes or other cellular 
proteins and inactivate them. Given the short-life of superoxide, it will react only 
with thiols in the immediate vicinity of its formation.
Superoxide can, however, initiate a cascade of events that can ultimately 
cause significant oxidative damage. A critical component
of this cascade can be seen in figure 5, this interaction of the superoxide
2+molecule with hydrogen peroxide in the presence of ferrous (Fe ) ions produce 
the highly reactive hydroxyl radical (OH ). The OH radical thus generated can
23,26,27result in significant cellular damage . Superoxide can mobilise iron from
28,29 30intracellular ferritin stores . Ferritin contains ferric iron that can be reduced
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by superoxide to the ferrous form and thus liberated to participate in free radical 
generating reactions or a series of other important events in free radical induced
31,32cellular Injury. In addition, some groups consider that superoxide can react 
with ferric iron to form the oxidising perferryl radical (Figure 8).
S equence of Events Leading to Free Radical induced Ceiiu iar Injury,
Direct Damage to Cellu lar 
Macromolecules
Free Radical
Generation Process
► HALS► Peroxidation► OH
Fe L iberation
G lutattilone Depletion and 
Oxidation of Protein Thiols
Generation of 
Perferryl Radical
Damage to  Cell 
Membranes
/  J.
Increased 
cPhosphollpase A g
I D ire c t C e llu la r  Damage~j - 
HALS = Four-hvdroxvl a ikanals
Cell Lysis
Cell Death
cPhospholinasB A „= Cytoplasm ic Phosphollpase A ;
Adapted from J. A. Brent et al : C linical Toxicology Vol. 31 ( 1 ), 139 - 171, 1993. 
Figure 8.
This ferrous-oxygen species may initiate lipid peroxidation. The perferryl ion, 
which is an intermediate species formed during reduction of Fe ( III) , may be
formed only if the iron ions are complexed by a chelator (e.g. ADP, ATP). In this
3+ 2+case superoxide would be involved in the reduction of Fe to Fe . Other
33authors argue that the perferryl ions are un reactive. The exact mechanism of 
the reaction of a ferrous chelate-oxygen complex with unsaturated fatty acids is 
unclear. However, most superoxide does not participate in the above reactions 
for several reasons. Superoxide has a very limited lifespan, forming hydrogen
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peroxide and oxygen by a dismutation reaction (Figure 4). Although this last 
reaction occurs spontaneously, as has been noted it is further promoted by the
33enzyme superoxide dismutase (SOD) .
The superoxide radical is capable of limited cellular damage itself but may 
initiate a sequence of events (Figures 8 & 9) leading to considerable oxidative 
injury.
M echanism  of Free Radical Induced C ellu lar Injury by the Redox Cycling Pathway  
Adapted from J, A. Brent et al ; Clinical Toxicology Vol. 31 ( 1 ). 139 - 171, 1993.
Toxin
Liboratad 
from FerritinSOD Cell Injury
G lutathione NADPToxin* G lutathione
Reductase
GSSGCatalase NADPH + H*
G lutathione
Peroxidase
GSSG -  an oxidised g lutathione dimerSOD = Superoxide Dismutase
F ig u re  9.
Endogenous antioxidant cellular defences, coupled with spontaneous 
dismutation of superoxide, limit its effect. However, under conditions of 
excessive superoxide formation or GSH depletion, superoxide can be predicted 
to have a more pronounced effect.
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1.2.2 Hydrogen Peroxide
Hydrogen peroxide (H^O^) is a potentially strong oxidising agent. It is
formed, as previously described in figure 4, by the dismutation of superoxide. 
Once formed, hydrogen peroxide may either cause oxidative damage directly or, 
like superoxide, initiate a sequence (Figures 8 & 9) that generates highly reactive 
free radicals. The direct damage caused by hydrogen peroxide relates to its
23ability to oxidise protein thiols and deoxyribonucleic acid (DMA), causing strand
33 34breakage ’ . These effects are attenuated by the tendency for hydrogen
23peroxide to react slowly . More important is the role of hydrogen peroxide as a 
substrate for the Haber-Weiss reaction (Figure 5), This reaction forms the 
powerful hydroxyl radical. The principle effect of hydrogen peroxide, like 
superoxide, is its participation in a cascade leading to oxidative damage 
(Figure 9).
The potential for hydrogen peroxide induced oxidative damage is moderated by
35two major enzyme defences, the action of catalase (Figure 10) and glutathione
36peroxidase (Figure 11).
Action of Catalase
2 H^Og 2 H^O +
Figure 10
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Action of Glutathione Peroxidase
+ 2 GSH -> 2 H^O + GSSG
GSSG = an oxidised glutathione dimer.
Figure 11
These two enzymes have the capacity to convert hydrogen peroxide to 
unreactive molecules.
1.2.3 Hydroxyl Radical
The hydroxyl radical { OH ) is the most potent free radical found in
23biological systems . It is indirectly formed from the generation of superoxide 
and hydrogen peroxide, see section 1.2.2. The hydroxyl radical can react with
23.27,37,38 39virtually any cellular molecule, and its effects on lipids , proteins , and
40nucleic acids have all been implicated as its sites of action. Its action on the 
fatty acid component of membrane phospholipids have been suggested as
23,27,37,41essential events in cellular oxidative damage . As shown simplistically in
figure 12, the hydroxyl radical can abstract a methylene hydrogen from a fatty
• 42acid( LH ) forming a lipid radical ( L ) .
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Lipid Radical Formation
OH + LH —> HgO + L
Figure 12.
This lipid radical can react with adjacent lipids, creating further radicals, and
42causing a self-perpetuating sequence known as lipid peroxidation (LPO) . This 
will be discussed more fully in the section 1.3 on lipid peroxidation. As most free 
radical scavenging molecules are found in the aqueous phase, with tocopherois
43(principally a - tocopherol) a notable exception, lipid peroxidation is relatively 
remote to these defences.
The highly nucleophilic hydroxyl radical can react with thiols and thus
39damage membrane proteins . It can also react with both the deoxyribose
40backbone and bases of DMA causing damage to the genome .
This type of damage could be catastrophic for the cell and because of this 
animals have evolved enzymatic and non-enzymatic antioxidant defences to 
deal with the inevitable low-level production of free radicals during normal 
metabolism.
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1.3 Damage caused by free radicals: Lipid Peroxidation
Polyunsaturated lipids are integral to the entire supporting system of cells, 
including cell membranes, endoplasmic reticulum and mitochondria. Disruption 
of their structural integrity has dire consequences for cellular function.
The oxidative destruction of polyunsaturated fatty acids (PUFA) is particularly
42,44damaging because it proceeds as a self-perpetuating chain-reaction
It is generally accepted that the lipid peroxidation reaction process starts 
after hydrogen abstraction from an unsaturated fatty acid. An example the 
peroxidation process is given in figure 13. The lipid radical formed reacts with 
molecular oxygen, if present, to form a peroxy radical. With this step radical
45.46,47.48 _  Ichain-reactions can occur . The reaction products are
monohydroperoxides of lipids. These will break down spontaneously or with 
metal catalysts initiating further chain-reactions. The alkoxy radicals formed can 
undergo cleavage of the C - C bonds. The example given in figure 13 shows the 
simplest scheme for lipid peroxidation reactions. It demonstrates that the 
cleavage of the C - C bonds results in the formation of unsaturated fatty acid 
aldehydes and alkyl radicals, which in turn initiate new radical chain reactions. 
The formation of the alkanes ethane, /7-pentane and others during lipid
49peroxidation occurs by the mechanisms shown in figure 13 .
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Figure 13
In itia tion
Diene Conjuga t ion
i g .  CH 2-  CH = CH - CHg-  CH = CH - CH ^ C H  = C H ^  C H ^ j ^ - C O O H
HO
H„0
Linolenic Acid
CH g- CHg - CH = CH - CH - CH = CH - CH^ - CH = CH - ( CH COOH
C H g .  C H ^  - ÇH - CH = CH - CH = CH - C H g -  CH = CH - ( C H g j y  COOH
= CH - ( C H g)^- COOH 
Peroxv radical
C H ^ - C H - C H = C H  - C H  = C t . - v . , ,CH 3
R - C H  = Cl
C H
- C H  = Cl
R a d ic a l cha in  reaction
R - C H  = C
R' - C H  = C H  H
CH g- CH CH - CH = CH - CH = CH - CH 3-CH = CH - ( CH^ ) ^ - COOH
> 0 H H ydroperox ide
Fe 2*
y  ^  Fe 3+
CHî- CH -ÇH-CH=CH - CH = CH - CH CH = CH  ^( CH„),- COOHM3- ^Mg- (j
9 + H O
\
2 '7
A Ikoxv R ad ical
C H ^ -  C H ^ +  Q ^ C  - C H  = CH - CH = CH - C H j - C H  = CH - ( CH^ l y  - COOH
Acid A ld eh yd e
R - C H
R' - C H
.  R - C H  = C H ,^  .
/  \R' - C H  = C H ' H
C H g - C H ^  E t h a n o
S ch em e representing  the form ation  of e th an e  during lipid peroxidation  
induced by hydroxyl radicals.
Adapted from H. Kappus: In Oxidative Stress.
Ed. H. Sies: Academ ic Press, 273 - 309, 1985
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The 0)3 (18:3 ''''') unsaturated fatty acid (Linolenic acid,
9,12,15 " Octadecatrienoic acid) yield ethane, and the co6 (18:2"') un saturated 
fatty acid (Linoleic acid, 9,12 - Octadecadienoic acid) yield 
n-pentane. That transition metal ions are involved in lipid hydroperoxide
50,51,52,53 ^decomposition has been proved in vitro experiments . At least two
isolated double bonds are needed to form monohydroperoxides of fatty acids to 
form alkanes. AI ken es can also be formed.
The quantity of monohydroperoxides of lipids formed in biological systems 
is relatively low, as shown by studies measuring ethane and n-pentane. The 
major part of the lipid peroxidation process in biological systems seems to 
involve very complicated reaction sequences. One of these is presented in figure 
14, although hypothetical it is based on reaction products formed. The 
formation of endoperoxides during lipid peroxidation has long been established.
If this endoperoxy radical undergoes intramolecular rearrangement followed by a
2+reaction with oxygen and in the presence of Fe a lipid alkoxy radical is formed. 
Malondialdehyde is an important reaction product of the lipid alkoxy radical and 
is measured in biological systems that undergo lipid peroxidation. There are 
some indications that the decomposition of the cyclic lipid endoperoxy-
54,56hydroperoxide is catalysed by metal ions . The breakdown of cyclic 
endoperoxy-hydroperoxides would also yield un saturated lipid aldehydes and 
alkenyl or alkyl radicals that would also initiate radical chain reactions.
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Inilialion
Figure 14
R - CH = CH  - CH  2 CH = CH  - C H ^ - C H  = CH  - R'  L ipid
F e ^ * +  O g+ H + (  H O " )  — ^
Fe"" + HgO^( HgO )
R - CH  = CH  - C H „ -  CH  = CH - CH  - CH = CH - R'  L ip id Radica l
Diene Conjugation
,o - O,\
;
I - Cl-
H - Ci
R - CH  = CH - CH „• CH H = CH - CH = CH  - R' 
*0 -
R - CH - CH  - CH CH - CH  = CH - CH -  CH - R' L ip i d e nd op e ro x y  ra d ic a l
I n t ra m o le c u la r
re a r ra m g e m e n t i
R a d ic a l chiain re a c tio n
R - CH - CH - CH - CH  = CH - R' 
CH - CH
cW S h
R - CH  - CH  -  = CH - R' 
0 - 0
R - C H  = C H  - CH g - C H  = C H  - R"  
R - C H  = C H  - C H  - C H  = C H  - R"
R - CH  - CH - CH  - CH  = CH  - R'> K , . . .o - o
R - CH  - CH  - CH - CH = CH  - R ’ -r HO ■'"o*CH ^ C H
-  0 '
Lipid a ik o x v  ra d ic a i
*R - C H  = C H g  + O  =  C H  - C H  = C H  - R' 
Alkyl ra d ic a l Lip id  a id e h y d e
0 = C H  - C H g -  C H  = O  
M a lo n d ia ld e h y d e
R  =  C H  - C H g -  R ' = - { C H g )  - C O O H  R " =  - ( CH^ ) , -  C O O H
S c h e m e  re p res en tin g  the fo rm a tio n  o f m a lo n d ia ld e h y d e  during  lipid p ero x id a tio n  
ind u ced  by fe rro u s  - oxyg en  co m p lexes or by hydroxyl rad ica ls
Adapted from H. Kappus: In O xidative Stress.
Ed. H. Sies: A cadem ic Press, 273  - 309, 1985
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Reactions schemes as shown in figures 13 and 14 are only parts of very 
complex reaction sequences. Many more products have been detected from 
autoxidation experiments with PUFA or phospholipids. These additional 
compounds, such as hydroxy and epoxy derivatives, ketones, 
polyhydroperoxides, dimers and polymers of fatty acids, are formed during 
different radical chain reactions"^ ’^^ ’^ , but they are all derived from 
hydroperoxides or endoperoxides. In biological systems only a few of these lipid 
peroxidation products have been identified e.g. malondialdeyde, 
4-hydroxynonenal and the alkanes ethane and /7-pentane.
The most important events in lipid peroxidation are radical chain reactions. 
If they are not terminated by the reaction of two radicals they proceed 
concurrently, destroying all lipid phases, especially lipid membranes that contain 
many essential un saturated fatty acids. In addition lipid peroxidation generates 
diffusible toxic second messengers (Figure 8) such as 4-hydroxyl alkanals
58,59,60,61(HALS) . An example of a HAL is 4 - hydroxynonenal that is a major by­
product of 1,6 - arachidonic acid peroxidation. These molecules have been
62demonstrated to inhibit enzymes ( i.e. glucose-6-phosphatase ), increase the
63 58,59,63permeability of hepatocyte membranes , kill hepatocytes , lyse
64 65,66 67erythrocytes , inhibit protein synthesis , block DNA replication , inhibit
68 59mitochondrial respiration , and decrease membrane fluidity . The latter effect 
has been implicated in the activation of phospholipase A^ which catalyses the
59formation of lysophosphatides and has other important biological effects which 
will be discussed later. Doubts have been raised about the in vivo relevance of
69HALS as most experimental results are based on levels 100 times higher than 
would be found physiologically. However it has been postulated that intracellular
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HALS produced during hepatocyte lipid peroxidation may have higher
concentrations in the microsomes where they were generated, and therefore
59may be damaging to molecules at that site . Thus the precise role of HALS in 
the free radical cascade is yet to be fully determined.
1,4 Common Pathway of Cell Death.
It is clear that there are many aspects of cellular function affected by free 
radical generating systems. As shown in figure 8, as these effects progress and 
amplify a great number of cellular functions are compromised. Several aspects 
of cellular function have been singled out as the potential driver of cell death.
59,70Prominent among these are alterations in intracellular calcium homeostasis
71,72and cell lysis induced by cytoplasmic phospholipase A  ^ . Since all these
process occur simultaneously in the cascade of toxic cellular injury, it is difficult 
to isolate a single factor as the specific mediator of cytotoxicity.
Cells normally maintain a large calcium gradient with the extracellular fluid
3 4that contains 10 to 10 times as much of this cation as the cytosol. One 
response to xenobiotic cellular damage is inhibition of thio-dependent calcium
59,70,71dependent homeostatic enzymes . Although several free radical- 
generating xenobiotics cause a loss of calcium homeostasis, this has been best 
studied following carbon tetrachloride poisoning, in which an increase in
73,74,75cytosolytic calcium occurs within and hour of poisoning . This calcium influx 
appears to be more than a non-specific effect on enzymatic mechanisms
76.77because inhibition of sodium/potassium ATPase occurs hours later . At such 
time there is a general compromise of cell function, membrane permeability non-
76.78specifically increases and there is a large secondary calcium influx that
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78marks a pre-terminal event for the cell . However calcium influx has been 
questioned as the cause of cell death as a 8-fold increase in cytosolic calcium
79with ionophores does not seem to adversely affect the cell .
The enzyme phospholipase (Type IVA)^° has been suggested as an
important component of free radical effects, and there is good evidence to
59,72 59 81,82,83support this idea . Lipid peroxidation , HALS , and an increase in
intracellular calcium have all been demonstrated to decrease membrane fluidity 
and increase membrane permeability which stimulates phospholipase A .^ In
72,83,84addition, a rise in intracellular calcium directly activates phospholipase A^
This enzyme catalyses the release of arachidonate and to a lesser extent 
eicosapentanoic fatty acids from the lipid membrane and forms of
59,72lysophosphatides, which can result in cellular lysis . In addition arachidonate 
is the source of prostaglandins and biologically active eicosanoids. Whether 
there is a single or multiple mediators leading to cellular death remains to be 
elucidated.
1.5 Primary defence systems against oxidative threat.
Living in an oxidative environment, aerobic organisms have evolved a series of 
endogenous free radical protecting, or scavenging, systems. Antioxidants are the 
primary defence mechanisms against oxidative threat. As shown in Table 1, such
85,86a system encompasses many substances that are often called by such 
generic names as antioxidants, free radical scavengers, chain terminators or 
reductants. The antioxidant systems responsible for cellular protection against 
oxidative stress are as diverse as the free radicals themselves. To provide 
maximum protection, cells contain a variety of substances capable of scavenging 
many different species of free radicals, including lipid peroxides and organic
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carbon-centred free radicals (Table 1). These scavengers are strategically 
compartmentalised in subcellular organelles within the cell to provide maximum 
protection. For instance, superoxide dismutase (SOD), catalase (CT) and 
glutathione peroxidase (GSH-PX) are not only distributed in the cytosol but are 
also localised in mitochondria, where most of the intracellular free radicals are
87,88produced . In the red cell as much as 10% of its energy supply is routed 
through the hexose monophosphate shunt and provide a source of reductants 
through NADPH. Although considerable progress has been made in identifying 
and understanding the mode of action of individual enzymes and antioxidant 
defence components, the complexity of the intracellular network of various 
antioxidants has impeded understanding of the overall protective efficacy of the 
cytosolic defence system.
In addition to the integration of intracellular cytosolic defences, the co­
operative interaction between the various antioxidants in extracellular fluids 
including plasma is crucial for maximum suppression of free radical reactions in 
these compartments.
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Category Structure Tissue Site Actions
Enzyme Systems
Superoxide dismutase Cu/Zn SOD 
Mn SOD 
Cu SOD
Primarily cytosol, also 
nucleus.
Primarily mitochondria. 
Primarily plasma
Catalyse dismutatlon of 0^ to H^O^.
Catalase Terameric
hemoprotein
Peroxisomes Catalyses dismutation of H^O^, reduces 
methyl and ethyl hydroperoxides.
GSH redox cycle
GSH peroxidase Selenoprotein Primarily cytosol, also 
mitochondria.
Cataiyses reduction of H^O^ and other
hydro- peroxides (lipid peroxides, 
lipoxygenase products).
GSH reductase Dimeric protein Primarily cytosol, also 
mitochondria.
Catalyses reduction of low molecular weight 
disulphide s.
Fat-soluble Compounds
Vitamin E Fat- soluble Vitamin Lipid membranes, 
extracellular fluids 
(including alveolar)
Converts 0^ , OH, and lipid peroxyl radicals 
to less reactive forms. Breaks lipid chain 
reactions.
P-Carotene Metabolic precursor to 
Vitamin A.
Membranes o f tissues Scavenges , reacts directly with peroxyl 
radicals
Bilirubin Product o f hemo­
protein catabolism.
Blood stream, tissue. Chain breaking antioxidant. Reacts with 
ROO..
Water-soluble Compounds
Vitamin C Water-soluble Vitamin Wide distribution in Infra- 
and extra-cellular fluids. Directly scavenges and OH. Neutralisesoxidants from stimulated neutrophils. 
Contributes to regeneration of vitamin E (in 
vitro).
Uric Acid Oxidised purine base Wide distribution. Scavenges 0^ , OH, and oxohaem 
oxidants, and peroxyl radicals. Prevents 
oxidation of vitamin C.
Cysteine Amino acid. Wide distribution. Reduces various organic compounds by 
donating electrons from sulphydryl groups.
GSH Tripeptide. Largely intracellular, also 
alveolus.
In addition to role as substrate in GSH redox 
cycle reacts directly with O^ , OH and 
organic free radicals.
Table 1
Major Antioxidant Scavenging Components
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1.5.1 Classification of Antioxidants
The antioxidant defence systems traditionally have been termed “primary” 
or “secondary” to designate the scavenging action of antioxidants. Primary
defences interact with free radicals generated directly from (namely ):
-• 89secondary defences scavenge radicals arising from dismutation of 
(Figure 15).
C T S O D [IO-
vitanttn E viin/nin < uric cicid P'CarnMir
s e c o n d a r y  d e f e n s e  s y s t e m s  
r n ( lo } ’ e n o t(s  c / t r /c n o rs  jn y jf c d x c s  t ip o s c s  D N A  e x c is io n  r v in u r
transition m eta l ions C a ta lase H - , ( >  4 ( ) ,
N i ic k ' i c  A c id s  
P ro te in s  (^ olysacOtaritk's 
L ip id s
K- loseI 4Q ii.ita lh jone-S -transfc!iase  
o r n o n en zym atick t)( >1
k (  )i  1
G S  1
G iL ita ttn o iu
R e d u c ta s eG lu ta ttiio n ePtsroxidase
G S S C
NAIM
/  i t x i c i t y
various  en^yino;, 
tra n s h y d io g o n a tio r
Biological antioxidant defence systems. All aerobic cells contain a spectrum of chemical and 
enzymatic antioxidants. These work in concert to minimise the initiation and propagation of 
undesirable oxidative reactions within cells (primary defence) or to repair damage (secondary 
defence). Adapted from: Natural Antioxidants in Human Health and Disease (1994) Ed., Balz 
Frei. Academic Press.
Figure 15
Some investigators more broadly classify the various chemical antioxidants 
themselves as the primary defence component and scavenging enzymes as the
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secondary defence component.
As the knowledge and understanding of free radical biochemistry 
increases, the scope of the term defence system has also broadened to 
encompass several major enzymes involved in the removal or repair of damaged
90,91,92,93,94 89cell constituents . Davies has proposed the following as a
comprehensive classification of antioxidant defence systems. Primary defences 
include antioxidant compounds such as vitamins A, C, and E, glutathione, and 
uric acid. Also included under the primary defence classification would be the 
antioxidant scavenging enzymes such as SOD, CT and peroxidases. For 
secondary defences, he suggests lipolytic enzymes, phospholipases, proteolytic 
enzymes, proteases, peptidases, DNA repair enzymes, endonuclease, 
exonuclease and ligase.
1.5.2 Vitamin E.
Vitamin E is the most widely distributed antioxidant in the plant and animal 
kingdoms. Vitamin E is a generic term for a group of tocol and tocotrienol 
derivatives that contribute to some degree to vitamin E activity. It is known to be 
a mixture of 4 tocopherois (alpha, beta, delta and gamma (Figure 16)).
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Vitamin E
^2 R3
oi-Tocopherol CH3 CH3
^-Tocopherol CH3 H ^16^33
y-Tocophero! H CH3 ^16^33
8-Tocopherol H H ^16^33
Figure 16: Structure of Tocopherois
a-Tocopherol is the major form of vitamin E in human plasma and tissues and
96is the most potent of the four naturally occurring tocopherois .
Vitamin E is found in the diet primarily in vegetable oils and also in cereal 
grains, green plants, egg yolk, milk fat, liver, nuts and vegetables. Based on 
studies of induced vitamin E deficiency in humans and assessing levels of 
vitamin E required to prevent hydrogen peroxide induced haemolysis, the new 
United States Recommended Daily Allowance (RDA) for men and women was 
set at 15 mg/day® .^ There is no United Kingdom Reference Nutrient Intake (RNI) 
although it has been suggested that an intake of 5 mg/day and 7 mg/day is 
appropriate for adult women and men respectively®^.
The absorption of vitamin E is incomplete, varying between 21% and 74%, as 
dietary factors influence émulsification and solubility in mixed bile salt micelles 
and thus the uptake of tocopherois by the small intestine. Although plasma carrier 
proteins have been described for other fat-soluble vitamins, such as the retinol- 
binding protein ®® no plasma carrier proteins have been discovered for vitamin E. 
Although vitamin E is present in all of the lipoprotein fractions, it is the low and 
high density lipoproteins (LDL and HDL) that are the major vehicles for transport 
in human plasma 100,101,102.103  ^ Studies have documented that vitamin E can 
exchange between lipoproteins and red blood cells and between plasma and
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red blood cells . a-Tocopherol, which exchanges more slowly than cholesterol 
but much more rapidly than triglyceride, does not require a transfer protein for 
exchange to occur One route by which at least some tissues probably receive 
significant amounts of vitamin E is via the LDL receptor mechanism. This 
mechanism would simultaneously deliver to cells peroxidizable lipids, such as 
linoleic acid and the antioxidant, vitamin E. Tissues with relatively high levels of 
LDL receptors, such as the adrenal gland, may obtain most of their a-tocopherol 
in this way. Another mechanism available for vitamin E uptake involves 
lipoprotein lipase, which is present in the circulation on the endothelial lining of 
capillary walls and hydrolyses triglycerides in chylomicrons and VLDL to free fatty 
acids and monoglycerides In vitro, this enzyme functions as a transfer protein 
for vitamin E during lipolysis of triglyceride-rich lipoproteins and emulsions It 
is likely that tissues with high levels of lipoprotein lipase activity, such as adipose 
tissue and muscle, might transfer significant amounts of vitamin E by this 
mechanism. The brain also has been reported to have lipoprotein lipase activity 
which might serve to mediate some vitamin E transfer into this organ. 
a-Tocopherol enrichment of plasma and tissues is mediated by the 
a-tocopherol transfer protein (a-TTP), a cytosolic lipid-transfer protein expressed 
in the liver iio-i 11-112.113  ^Although the mechanism Is unknow n^a-TTP is 
believed to selectively transfer a-tocopherol from lipoproteins taken up by 
hepatocytes via the endocytic pathway to newly secreted lipoproteins, which 
facilitate its delivery to peripheral tissues^ Humans with a-TTP gene defects 
have extremely low plasma a-tocopherol concentrations and develop severe 
neurodegenerative disease unless they are treated with high doses of vitamin 
1^15.116.117 ji^jg ppotein specifically transfers RRR-a-tocopherol. As vitamin E is
transported in plasma within lipoproteins its plasma concentration varies with the
118total lipid (cholesterol, triglyceride and phospholipid) . a-tocopherol being 
extremely lipophilic is therefore found predominantly in plasma lipoproteins and 
membrane fractions where it is a potent chain-breaking antioxidant (Table 1).
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Vitamin E scavenges the chain-carrying peroxyl radicals rapidly and interrupts
119,120chain propagation. For this reason it is the major lipid-phase antioxidant . a- 
tocopherol has been demonstrated to inhibit hepatocyte lipid peroxidation caused
96,121 122,123,124 , , 96by ethanol , carbon tetrachloride , and diaquat . When microsomes
are challenged by one of these xenobiotics there tends to be a lag phase before 
initiation of lipid peroxidation. This time period corresponds to the time required
125for the depletion of microsomal a-tocopherol . a-tocopherol ( a-TocH ) was 
previously described as a chain-breaking antioxidant because it reacts with lipid 
peroxyl radicals (Figure 17).
LOO + a-TocH a-TocH + LOOH 
Figure 17.
The reaction shown above interferes with the chain-propagating step of lipid 
peroxidation. One molecule of vitamin E scavenges two molecules of peroxyl 
radicals as follows:
• It first scavenges a peroxyl radical and donates a hydrogen atom to yield lipid 
hydroperoxide and vitamin E radical.
• Vitamin E radical does not propagate the chain but reacts with another 
peroxyl radical rapidly to give a stable adduct.
• This adduct may further react with peroxyl radical to give the epoxide and 
alkoxyl radical.
Alpha- tocopherol is also known to react with lipid radicals in an analogous
26fashion . Once formed, the alpha-tocopherol radical may be reduced by
126GSH (Figure 18).
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2 Œ-TocH +2  GSH 2 a-TocH + GS-SG
Figure 18
It has been found, in erythrocyte membranes, that vitamin E can be 
protected by either NADH-cytochrome - dependent enzymatic recycling or by
a nonenzymic pathway involving ascorbate (Figure 19) 127
Dehydroascorbate
AscorbateVitamin E < 
( chromanol )
LOO
Cytochrome bs 
( Oxidized ) NAOH- Cytochrome bs 
\  reductaseVitamin E 
Radical T  
Chromanoxyi
LOOH
Cytochrome bs 
( Reduced )
Scheme showing the possible enzvmic and nonenzvmatic pathways of vitamin E recycling in
human erythrocyte membranes. Adapted from Constantlnescu et al
Figure 19
The level of vitamin E in the human erythrocyte membrane is relatively low
compared with plasma levels, the ratio of these two amounts being
128approximately 1:3 . Nevertheless, normal erythrocytes from healthy subjects
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do not contain any significant amounts of lipid peroxides when freshly
129,130isolated . This observation could have two possible explanations:
1) oxidised vitamin E is constantly replaced by fresh (reduced) vitamin E from 
the plasma lipoprotein pool, or
2) oxidised vitamin E is restored to its reduced form in situ by enzymatic and/ or 
nonenzymatic processes.
The first possibility is still a subject of debate, since neither the diffusion of 
reduced vitamin E from plasma to membranes occurs rapidly enough to 
replenish the oxidised molecules and no direct experimental evidences exists to 
support the hypothesis of a specialised carrier, which replaces oxidised with 
reduced vitamin E. As for the second possibility, it is now generally accepted that 
vitamin E radicals generated in various types of membranes can be reduced by 
compounds naturally present in biological systems. These compounds can be 
either reducing agents or substrates for redox enzymes contained in the
131,132,133,134membranes
Among the reducing agents is vitamin C, which functions as a water- 
soluble chain-breaking antioxidant and acts synergistically with vitamin E to 
protect both endo- and plasma membranes from oxidative damage. Vitamin C 
regenerates vitamin E by directly reducing tocopheroxyl radicals generated when
135vitamin E scavenges reactive free radicals . This interaction between the 
radicals of these two vitamins can take place in the erythrocyte membrane too, 
where vitamins C and E reside separately outside and within the
136,137membrane, respectively . It should be noted that the sparing action of 
vitamin C for vitamin E does not always indicate a synergistic effect by both 
vitamins. When radicals are generated initially in the aqueous region and attack
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membranes from outside, vitamin C and other water-soluble antioxidants can 
scavenge the radicals in the aqueous phase before the radicals attack the 
membranes, hence vitamin E in the membranes may not be consumed initially. 
Vitamin E traps radicals after most of the antioxidants in the aqueous phase are 
used up and the radicals reach the membranes. In this case, the inhibitory effect 
is not synergistic but additive. On the other hand synergistic inhibition takes 
place when radicals reaching the membrane lipids or radical generation within 
the membranes leads to the production of the vitamin E radical which is reduced 
by vitamin C to regenerate vitamin E. There is doubt as to whether this reaction 
involving vitamin C occurs in humans, at the membrane aqueous interface, in
138vivo as it has not been unequivocally proven. However there are a few 
publications, which imply that this interaction takes place in biological
139, 140systems . Enzymatic recycling of vitamin E has been demonstrated in
132,141many types of biological systems, including mitochondria , rat liver
131,132,142 143microsomes , and human platelets . No data are available, however,
for enzymatic vitamin E recycling in human erythrocyte membranes.
In the endomembrane of microsomes and mitochondria, 
chromanoxyi radicals of vitamin E can be reduced to form chromanols by 
NAD(P)H-dependent enzymes. Plasma membranes of various cell types 
(including erythrocytes) also contain NAD(P)H oxidoreductase enzymes, as well
144as flavins, thiols, 6-type cytochromes and coenzyme , which could play a
role in vitamin E recycling. Specifically, the erythrocyte membrane contains a 
transmembrane NADH-ferricyanide reductase associated with both proton
144,132movement out of cells and the activation of membrane proteins by
145phosphorylation , as well as NADH-cytochrome c reductase on the inner side
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146of the membrane that is antigenicaily identical to NADH-cytochrome
147reductase of endoplasmic reticulum . The natural substrate for this latter 
enzyme, which is not known to be involved in any transport function or fatty acid
144desaturation process , is still the subject of debate, since two fractions that 
seem to have different substrates (a soluble one and a membrane bound one) 
have been isolated.
The role of vitamin E in the human body is not clearly established, but it is 
known to be an essential nutrient in more than 20 vertebrate species. The 
vitamin plays some role in forming red blood cells and muscle and other tissues 
and in preventing the oxidation of vitamin A and fats.
Vitamin E supplementation is popularly advocated for a wide range of 
diseases, but no substantial evidence has been found to back these claims. The 
report of the panel on Dietary Reference Values of the Committee on Medical 
Aspects of Food Policy records that few adverse effects have been reported 
from doses of vitamin E up to 3200 mg/day although the usual intakes were 3.5 
mg to 19.5 mg per day in adult men and slightly lower in women^®. Although 
vitamin E is stored in the body, overdoses appear to have lower toxic effects
148than do overdoses of other fat-soluble vitamins
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1.5.3 Vitamin C ( Ascorbic Acid ).
Vitamin C is important in the formation and maintenance of collagen, the 
protein that supports many body structures and plays a major role in the 
formation of bones and teeth. It also enhances the absorption of iron from foods 
of vegetable origin. It is widely distributed in mammalian tissues, but it is present 
in relatively high amounts in the adrenal and pituitary glands. Lesser amounts 
are found in the liver, spleen, pancreas and brain. Although excess ascorbic acid 
is quickly excreted in the urine, large and prolonged doses can result in the 
formation of bladder and kidney stones due to increased production of oxalate, 
the destruction of concomitantly ingested B12, facilitation of too much iron
149absorption, and the loss of calcium from bones . Sources of vitamin C include 
citrus fruits, fresh strawberries, cantaloupe, pineapple, and guava. Good 
vegetable sources are broccoli, Brussels sprouts, tomatoes, spinach, kale, green
150peppers, cabbage, turnips and because of its importance in the diet, potatoes 
The Estimated Average Daily Requirement (EAR) for adult males and females is 
25 mg per day with higher requirements probably in smokers. The RNI is defined 
as two standard deviations (2SD) above the EAR. For Vitamin C this is 40 
mg/day^®.
In contrast to vitamin E, vitamin G (Figure 20) is hydrophilic and is
therefore more prevalent in an aqueous environment than vitamin E. Its role as
an antioxidant is indicated by its known free radical scavenging action. As a 
reducing and antioxidant agent, it reacts with and OH and various lipid
hydroperoxides. As has been shown in section 1.4.2 it has a possible role in the
127recycling of vitamin E
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OH OH
HO OH HO
AscorbateAscorbic Acid
OH
Dehydroascorbic Acid
Figure 20
When compared with other water-soluble antioxidants, vitamin C offers the most
151, 152,153effective protection against plasma lipid peroxidation by scavenging
free radicals before they damage plasma lipid components such as low density 
lipoprotein (LDL). If the previously discussed recycling action of vitamin C on 
vitamin E is proven then its action would spare vitamin E and allow it to protect 
against LDL oxidation.
However, vitamin C as well as being an antioxidant can also be a
139,154,155prooxidant . Vitamin C exerts a sparing effect on the antioxidant effects
of vitamin E and selenium. On the other hand, excess amounts (~ 1mM) may act
3+ 2+as a prooxidant in the presence of the transition metals Fe or Cu by
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generating cofactors of activated oxygen radicals during the promotion of lipid
156,157,158peroxidation. Several studies have shown that vitamin C’s prooxidant
3+action, which induces lipid peroxidation, resides in its ability to reduce Fe to the
2+ 2+Fe state; Fe is known to be a potent free radical producer. A study by
158Aruoma et al provide good examples for such interactions with metals, 
thereby inducing the prooxidant property of ascorbate. In this study, oxidative 
modification of DNA bases was substantially enhanced In the presence of 
ascorbate. The complexity of a dual role of vitamin C becomes magnified when 
other antioxidants like vitamin E are present (as in in vivo conditions). For 
instance, lipid peroxidation of microsomes is enhanced by vitamin C in vitamin E 
deficient animals but suppressed by vitamin C under normal conditions. However 
it has been pointed out that the concentrations of copper and iron complexes 
required to accelerate free radical reactions are not generally available in the
159extracellular fluids of the human body . The antioxidant properties of vitamin C 
in the human body will normally predominate, except in metal overload disease
159states . Although more studies are required, it appears that the concentration
and subcellular localisation of vitamin C might be important factors contributing 
to the sharply contrasting actions of this vitamin. As the pK^ of ascorbic acid is
4.25, the ascorbate anion (AH ) is the predominant form existing at the 
physiological pH. Ascorbate (AH ) oxidatively forms dehydroascorbic acid (DHA) 
through a reversible oxidation with the intermediate formation of the ascorbyl
radical (A  ). It has been suggested that DHA may be more effective than
2+ 160 ascorbate against Cu -induced lipid peroxidation in low density lipoproteins
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1.5.4 Carotenoids and Retinol ( Vitamin A ).
Vitamin A is available in the diet, either as preformed vitamin A (retinol) or 
from carotenoids which are cleaved to retinol in the body. Major sources of
carotenoids are vegetables and fruit, e.g. carrot, tomato, grapefruit, broccoli,
161orange and mango . They are absorbed from the intestine with an absorption 
efficiency inversely related to caroteniod intake. Absorption is particularly low 
when intake of dietary fat is low. The main carotenoids are a- and p-carotene 
and cryptoxanthin. Dietary vitamin A is available in the form of provitamin A 
precursor compounds cleaved enzymatically in the intestinal mucosa or liver to 
retinol^® ’^ ®^^ or directly from animal food: liver, milk, egg and fish . Lipoproteins 
and retinol-binding protein are responsible for the transport and plasma
165regulation of retinol (vitamin A) . p-Carotene and lycopene (major dietary
166carotenoids) are transported primarily within low density lipoprotein (LDL) . 
Structures of these molecules are shown in figure 21.
CH. CH.
"CHCH,CH. CH.CH. B-Carotene CH.
CH. CH.
CH CH CH. 'CH.C H . Lycopene
CH.,CH- CH,
CH
Retinol (Vitamin A)
Figure 21
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Estimated Average Requirements (EAR) of vitamin A for males and females is 
496 |ig and 402 |ig respectively per day as retinol. The carotenoids have long 
been considered antioxidants because of their capacity to scavenge free radicals
167,168,169 . Carotenoids protect lipids against peroxidation by quenching free
170,171,172radicals and other reactive oxygen species, notably singlet oxygen . The1quenching of singlet molecular oxygen ( O^) results almost entirely from energy
transfer and yields ground state oxygen and a triplet excited carotenoid. The 
energy is dissipated through the interaction between triplet excited carotenoid 
and the solvent (Figure 22).
1 + carotenoid ^  + carotenoid
carotenoid -> carotenoid + heat.
Figure 22
1However the contribution of p-carotene to the quenching of is minor in vivo
171and can be ignored . p-Carotene displays an efficient biological radical- 
trapping antioxidant activity through its inhibition of lipid peroxidation induced by
169the xanthine oxidase system . The structural arrangement of p-carotene 
(Figure 21) with their long chains of double bonds suggests that they would 
make excellent scavengers for reactive free radicals. The bleaching of
135carotenoid colour upon oxidation supports this idea. The antioxidant action of
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173carotenoîds has also been demonstrated in vivo with regard to lipid 
peroxidation.
p-Carotene reacts with the superoxide radical and forms a p-carotene-
superoxide radical addition complex, whereas lycopene undergoes a reversible
electron transfer with the superoxide radical. p-Carotene as well as retinoic acid
(widely used in the treatment of skin diseases) and its methyl ester inhibit lipid
peroxidation at low oxygen tension, whereas at high oxygen tension they exhibit 
prooxidant activity. At very low pO^ of 4 mm Hg, p-carotene inhibits lipid
173peroxidation even more effectively than a-tocopherol . However it should be 
noted that normal oxygen tension in human arterial and venous blood is about 
83 “  108 mm Hg and 40 -  61 mm Hg respectively and therefore it is unlikely that 
oxygen tensions of 4 mm Hg would occur in a healthy individual but may do so in 
peripheral tissue in vascular shut down, or in ischaemic tissue.
Plasma retinol concentrations are insensitive indicators of vitamin A status 
because a homeostatic mechanism maintains them at a reasonably constant 
level over a large range of liver reserves. They fall unequivocally below 
0.7 jiimol/L only in later stages of deficiency®®.
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1.5.5. Glutathione
Glutathione (Figure 23) is an important water-soluble antioxidant and 
reducing agent, synthesised from glutamate, cysteine and glycine in many cell 
types and present intracellularly in the millimolar range.
Glutathione Synthesis Pathway
COOH
Glutamic Acid + Cysteine
CH.
ATP
CH. y-glutamyl-cysteine
synthetase
ADPHN
CHHS CH.
y-glutamyi-cysteine
HN
CH. ^  Glycine
glutathione synthetase
ATP
COOH
Glutathione ADP
GSHNADP
( glutathione 
peroxidase )( glutathione reductase )
NADPH GSSG
GSSG = Oxidised glutathione. GSH -  Reduced glutathione.
Glutathione structure and synthesis pathway
Figure 23
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it acts as a substrate or cosubstrate in numerous enzymatic reactions e.g. the 
glutathione peroxidase reaction.
Reduced glutathione (GSH) is the most abundant low molecular weight 
thiol present in virtually all cell systems. The intracellular concentration is
174,175generally = 0.5 mM but sometimes reaches levels as high as 10 mM
Reduced glutathione is characterised by its reactive thio group and its
y-glutamy! bond, which makes it resistant to peptidase attack. Its versatility
arises from chemical properties that allow it to serve as both a nucleophile and
an effective reductant by interacting with numerous electrophilic and oxidising 
compounds such as H^O ,^ and OH. As an effective reductant, GSH plays
an important role in a variety of detoxification processes. This includes the 
nullification of peroxide damage, as evidenced by GSH depletion, which 
increases the susceptibility of animals to cytotoxicity and affects drug
175interventions in neoplastic diseases
Reduced glutathione readily interacts with free radicals, notably hydroxyl 
and carbon radicals, by donating a hydrogen atom. Such reactions can provide 
protection by neutralising reactive OH that Is considered a major source of free 
radical damage. The existence of a GSH-dependent factor that inhibits lipid
176,177peroxidation in membranes has been suggested . Such inhibition may be 
related to a catalytic amount of vitamin E that undergoes a series of reaction 
steps involving the regeneration by GSH (Figure 24)
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R + Vitamin E ^  r h  + Vitamin E + GSH Vitamin E + GS
2GS GSSH + NADPH 2GSH + NADP
Figure 24
As with most antioxidant defences, the levels of GSH fluctuate under
174,178various physiological conditions, including ageing and some neoplastic
179diseases that are usually accompanied by increased lipid peroxides . Whether 
this inverse correlation between the lower content of GSH and the higher level of 
peroxides represents a causal relationship is not yet established. Some studies
179 showed that a decrease in GSH levels with age may be due to either an 
increase in the oxidation rate or to a decrease in overall GSH turnover resulting 
from an increased degradation and/ or reduced biosynthesis of total GSH. 
Biosynthesis of GSH (Figure 23) from its constituent amino acids is catalysed by 
glutamylcysteine synthetase and GSH synthetase. In cells other than 
erythrocytes, y-glutamyltransferase (which also degrades GSH conjugates 
produced by glutathione transferases) can break down GSH. This enzyme is 
located in the plasma membrane with its active site facing the extracellular space 
where it acts on GSH and transfers the glutamate residue on to other amino 
acids such as cysteine, methionine and glutamine.
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1.5.6 Other Antioxidants.
Uric acid has traditionally been considered merely as an end product of 
purine metabolism in humans. However, its function as a biological antioxidant
has been increasingly recognised. The in vitro scavenging of OH by urate was
180first reported in 1960 by Howell and Wyngarden . Its antioxidant action was
85confirmed by its protection against oxidative damage . Recent renewed interest
181.,182in uric acid has focused attention on its role as a physiological antioxidant 
Although the precise biochemical mechanism of the antioxidant action of urate is 
not well defined, reports indicate that uric acid may act by preserving (sparing)
183plasma vitamin C , probably by complexing transition metals such as iron and
182copper . it has been shown that uric acid, located in the cell cytosol, cannot
184scavenge radicals within the liposomal membranes . Thus it acts against 
radicals generated in the aqueous phase not lipid derived radicals. It has been 
shown that aqueous radicals can be trapped by uric acid before they attack 
membranes.
Catalase (CT) is a major primary antioxidant defence component
185(figure 9) that primarily works to catalyse the decomposition of H^O  ^to H^O
(figure 10), sharing this function with glutathione peroxidase (GSH-PX). Both 
enzymes detoxify oxygen-reactive radicals by catalysing the formation of H^O^
derived from superoxide. In the presence of low H^O  ^levels, organic peroxides
are preferentially catalysed by glutathione peroxidase. However, at high H^O^
concentrations, there are metabolised by catalase. Like SOD, the tissue 
distribution of CT is widespread. The level of activity varies not only between 
tissues but also within the cell itself. The liver, kidney and red blood cell possess 
relatively high levels of CT. In hepatocytes, peroxisomes exhibit an expectedly
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13high CT activity, although activity was also found in the cytosol . CT is not a
6circulating enzyme and has a half-life of only minutes .
Glutathione Peroxidase (GSH-PX) is located intracellularly in the cytosol
186and mitochondrial matrix . It catalyses the reduction of H^O  ^(figure 11) and 
organic hydroperoxides (figure 25).
Glutathione Peroxidase reduction of Organic Hvdroperoxide.
2GSH + ROOH GSSG + H^O + ROH
Figure 25
Both types of GSH-PX enzymes, selenium dependent and selenium,
independent, have been shown to catalyse the reactions in figures 11 and 25
and therefore protect against radical damage by reducing peroxides. However
they possess different substrate specificities. The selenium dependent
peroxidase is found in the cytosol and exhibits low capacity for the reduction of 
H^Og. The selenium independent peroxidase utilises organic hydroperoxides as
preferred substrate over H^O .^ The involvement of GSH and the possible 
participation of GSH-PX in the inhibition of lipid peroxidation were first reported
187 188by McCay et al and later by Burk
Another form of selenium-dependent GSH-PX associated with membranes
189, 190was reported by Ursini et al . This cytosolic protein exhibited GSH-PX
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activity on degradation of phospholipid hydroperoxide. Further investigations are 
required to elucidate its physiological function.
As selenium is required for the optimal activity of GSH-PX it has been 
found that deficiency depresses GSH-PX activity and therefore alters 
antioxidant defence systems. Selenium deficiency has little effect on SOD or CT
87activity . This indicates that antioxidant enzymes in liver and muscles are 
capable of adapting to this deficiency to minimise changes in antioxidant defence
capacity. In this regard, the adaptive response to selenium deficiency also
88includes a greatly increased hepatic glutathione transferase activity .
1.6 Secondary Defence Systems Against Oxidative Stress.
As previously suggested in section 1.5 the components for secondary 
defences against lipid peroxidation are; lipolytic enzymes and phospholipases, 
The following sections summarise their function.
1.6.1 Lipolytic Enzymes.
The biological importance of phospholipases in the cellular regulatory
191,192processes has been firmly established . However, their participation in 
defence mechanisms against free radical damage and cellular repair of 
damaged membrane structure was not fully explored until recently. Cells are 
equipped with various enzymes responsible for the reconstruction of damaged or 
altered membrane constituents. It has been suggested that phospholipase- 
mediated removal of damaged fatty acid moieties from membrane lipids could be 
an effective way to maintain membrane integrity and at the same time provide a
191means to regulate lipid turnover . Investigators have shown that the
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peroxidation of membrane lipids can stimulate the lipolytic action of
192phospholipase . The phospholipase A2 (PLA2) enzyme comprises a rapidly
growing superfamily of intracellular and secreted proteins, which hydrolyse the 
acyl-group at the sn-2 position of glycerophospholipids (Figure 26) to release 
fatty acids and ysophospholipids®°.
Sn1 ■ Fatty acid
Sn2 — Fatty acid 
PLAz
Sn3 -----.— ( ^  ——  Phospholipid head group
Figure 26
The diverse PLA2 enzymes have been classified into Groups for I to XI thus far.
Recent clinical studies suggest that calcium dependent secretory phospholipase
A2 (SPLA2) of group IIA may contribute to atherosclerosis and that their plasma
levels my predict cardiovascular events^® .^ increased levels of calcium
dependent cytoplasmic PLA2 enzyme of group IV has been found in red cells of 
schizophrenic patients^ ®"^ . The predilection of phospholipase A  ^for oxidised
lipids could have very significant physiological ramifications with regard to
membrane repair or detoxification process because it could provide cells with
additional protective mechanisms against lipid peroxidation. It has been
demonstrated that there is a correlation between age-related increase in 
phospholipase A^ of microsomal membranes and an increase in oxidatively
195altered lipid hydroperoxides of the same microsomes . It may be that 
phospholipase A2 enhances peroxidation or has a protective role in different 
clinical conditions.
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1.7 Disease States Associated with Free Radical Damage
1.7.1 Ischaemic Heart Disease
The pathological changes associated with the development of coronary 
heart disease take place over many years. These changes can be considered to 
be:
initial arterial injury 
• development of a fibrous plaque at the site of injury 
blood clot formation 
the myocardial infarction itself.
They arise from a series of abnormal physiological responses that are influenced 
by a wide array of factors"'®®. Some of these factors are genetic, some age 
related, some lifestyle related and some associated with diet. The incidence of 
coronary heart disease cannot therefore be attributed to a single aspect, let 
alone a single component of diet. The abnormal physiological conditions which 
affect the frequency and severity of injury to the coronary arteries include 
increased blood pressure, increased lipid peroxidation, an increased tendency 
for platelets to aggregate and an increased inflammatory response.
In turn, these are influenced by components of diet. For example, blood 
pressure is increased by high intake of salt, the ratio of sodium to potassium 
intake, alcohol intake and obesity. The potential for lipid peroxidation is affected 
by the susceptibility of the fatty acids in low density lipoprotein (LDL) particles to 
oxidation (polyunsaturates are most prone to oxidation) and the balance 
between prooxidants (e.g. free iron) and antioxidants
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(e.g. Vitamins E and C and p-carotene).
The build up of the fibrous plaque in the injured artery wall is determined 
by a series of factors which affect both lipid and thrombus deposition, e.g. raised 
plasma cholesterol (influenced by the fat, fatty acid and soluble fibre content of 
the diet), increased plasma fibrinogen (probably not affected by diet, though 
influenced by smoking), and increased plasma insulin levels 
(associated with centrally located fat disposition). The formation of a major 
thrombus and the severity of the heart attack will be influenced by factors, which 
affect blood coagulation and the regulation of heartbeat.
A concept that is gaining considerable support, sometimes referred to as 
the ‘antioxidant hypothesis' or ‘oxidised LDL hypothesis’, helps draw together 
some of these risk factors and suggests’ a mechanism by which atherosclerosis
197progresses and perhaps even how the initial injury to the artery occurs 
(Figure 27).
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LDL enters the blood vessel Intima where it is modified to become an inflammatory stimulant and 
then oxidized. Monocytes enter the intima, take up oxidized lipid to become foam cells and then 
die. The cholesterol released creates the lipid core. Smooth muscle cells form collagen to enclose 
the core.
[mm-LDL -  minimally modified LDL, OX. LDL -  Oxidised LDL, PG -  proteoglycan]
Figure 27: Processes in atherosclerosis plaque formation.
Adapted from; Davies, M. J.; B.J.Card. Vol. 4 Supp. 1,1997, 8 4 -8 7 .
It is this mechanism that may provide the link between the importance of fruit 
and vegetables, as well as other dietary sources of antioxidants, and the need 
for a moderation in fat intake.
Although high levels of cholesterol-rich LDL particles in the plasma are strongly 
associated with an increase of coronary heart disease, these particles are not
197atherogenic in themselves . Although they can enter the blood vessel wall, by 
way of classical LDL receptor mechanism (Figure 28), they do not create an 
inflammatory reaction or tissue damage.
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lipoprotein. IDL -  Intermediate density lipoprotein.TG -  triglyceride. APO Cl! - Apolipoprotein 
Cll is essential to the catabolism of VLDL and Chylomicrons. APO B -  the major protein moiety 
of all lipoproteins other than HDL and has a major role in ensuring lipid delivery to the 
extrahepatic cells. It allows the recognition and binding of LDL to specific high-affinity receptors 
on the cell membrane., ACAT -  Acyl-cholesterol acyltransferase, required for cholesterol 
estérification intracellularly. HMG-CoA Reductase -  3-hydroxy-3-methylglutaryl-CoA 
Reductase, required for endogenous cholesterol synthesis. + = positive feedback. - = negative 
feedback.
Figure 28: LDL Catabolism Via High Affinity Receptor Pathway foun^ d in Liver and 
Peripheral Cells ( Adapted from: Tietz Texbook of Clinical Chemistry 2" edition. Burtis C.
A.. AshwoodE. R.. Editors f1994l Chapter 23. page 1027.)
In contrast, LDL particles, which have been modified by oxidation, are no longer 
recognised by the LDL receptors on the cell surface and behave as if it is foreign 
material, in that they invoke an inflammatory response. This oxidised LDL (Ox- 
LDL) is taken up more avidly by macrophages than native LDL via the 
scavenger receptor mechanism that is not subject to regulation by the cellular 
cholesterol content^ ®®. The characteristics of oxidised LDL are given in Table 2.
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Table 2.
Characteristics of oxidized LDL 
Reduction in polyunsaturated fatty acids 
Increase in lipid peroxides.
Increase in negative charge of apoB 100*
Increase in oxysterol content.
Increase in lysolecithin content 
Fragmentation of apo B-100
Increased uptake by macrophage scavenger receptor.
Apo B 100 is the major apolipoprotein present in LDL particles
The reduction of polyunsaturated fatty acid in oxidised LDL is accompanied by
199, 200an increase in iipid peroxides and aldehydes . Extensive oxidative 
modification of LDL results in derivatization of lysine residues on apolipoprotein
B (apo B) by lipid hydroperoxides or aldehydes such as malondialdehyde, 4-
201hydroxynonenal and hexanal, thus increasing the negative charge on LDL
These changes in apo B lead to increased LDL uptake by the scavenger
202receptor on the macrophage
It is worthwhile reviewing this complex process. The initiating event for 
production of Ox-LDL is the peroxidation of poylunsaturated fatty acids on LDL. 
Figure 27 shows the scheme depicting the relationship between Ox-LDL (a 
potent chemoattractant for circulating monocytes) and the formation of the lipid 
accumulation in the artery wall, the fatty streak lesion.
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In the early phase of oxidation, mild oxidation of LDL results in the formation of 
minimally modified LDL (mm-LDL) in the subendothellal space. Once formed, 
mm-LDL may be able to induce the endothelium to express adhesion molecules 
for monocytes and to secrete monocyte chemotactic protein-1 (MCP-1) and 
macrophage colony stimulating factor (M-CSF). These events result in the 
monocyte binding to the endothelium and the subsequent migration of the 
monocyte into the subendothelial space. There, mm-LDL promotes 
differentiation into macrophages, via M-CSF, which in turn, modify mm-LDL into 
a more oxidized form. This Ox-LDL can then be processed by way of the 
scavenger receptor mechanism, thus leading to accumulation of cholesterol
203esters . As Ox-LDL is a potent inhibitor of macrophage motility, it may also 
promote retention of macrophages in the arterial wall. Products of LDL oxidation 
are cytotoxic and this cytotoxicity may be important in inducing endothelial cell 
dysfunction and in promoting the evolution of the fatty streak into a more 
complex and advanced lesion. Ox-LDL may be responsible for reduced 
fibrinolysis in blood vessels and may also promote pro-coagulant activity by
204inducing expression of tissue factor (TF) , a low molecular weight (45-kD) 
membrane bound glycoprotein. In addition to its regulation of coagulation it is 
also a critical determinant of thrombin generation in normal haemostatis and in 
atherothrombotic disease^®®’^ ®®. The binding of TF to factor VII is the first step in 
the extrinsic coagulation cascade. In human atherosclerotic vessels, TF is 
abundant, particularly within the acellular lipid core of the plaques and in the 
lumen where it is expressed by monocyte-derived macrophages^® '^^®®. The 
clinical consequences of inappropriately high intravascular expression of TF are 
often catastrophic. Intraluminal TF activity can trigger the thrombogenic cascade
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that underlies the often lethal thrombotic complications of atherosclerosis.
It has been shown that plasminogen activator inhibitor-1 (PAI-1) levels are
209increased in coronary heart disease . Ox-LDL causes endothelial cells in
culture to increase PAI-1 synthesis and secretion in a dose-dependent fashion
210 . It also Inhibits nitric oxide production and this, in turn, could promote 
vasoconstriction ^^^and platelet adhesiveness
Several lines of evidence can be cited in support of the in vivo existence of 
oxidized LDL (Table 3).
Table 3
Evidence for the in vivo existence of oxidised LDL (Ox-LDL).
Antibodies to Ox-LDL immunostain in rabbit atherosclerotic lesions.
LDL isolated from aortic atherosclerotic lesions have properties 
similar to Ox-LDL.
Autoantibodies In plasma of humans and rabbits react with 
Ox-LDL.
Antioxidants like butylated hydroxytoluene (BHT), diphenyl phenylenediamine 
(DPPD), probucol and vitamin E prevent progression of athersclerosis in animal 
models, it should be noted that BHT in doses >1% of the diet can cause hepatic 
and renal dysfunction and that DPPD is a mutagen.
A modified form of LDL that has many of the physical, chemical and biological 
properties of Ox-LDL occurs in arterial lesions. For example oxidatively modified 
and fragmented apo B has been isolated form the plasma of normal subjects 
and from patients with atherosclerosis Also, antibodies against epitopes on 
Ox-LDL recognize material in atherosclerotic lesions, but not in normal arteries; 
circulating antibodies against epitopes on Ox-LDL have been demonstrated in
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the plasma of Watanabe heritable hyperlipidaemic ( WHHL ) rabbits and in
215,216humans . The presence of autoantibodies against Ox-LDL has been
217positively correlated with the progression of atherosclerosis, as manifested by 
carotid artery stenosis. Also, it was recently shown that the susceptibility of LDL
to oxidation varied with the seventy of coronary atherosclerosis, as evaluated by
218angiography
It is thought that the oxidation of LDL is more likely to occur in the artery 
wall than in the circulation because of protective processes, which exist in the 
blood. The most important elements in the protection of LDL against oxidation 
are considered to be a combination of vitamin C in plasma and vitamin E in the
219LDL particle . It was originally believed that the accumulation of cholesterol in
the artery wall was the key to atherosclerosis but it is now clear that cholesterol
220itself is not a major factor during the formation of the lesion but follows later 
after damage has begun. There is evidence that the fatty streaks formed at the 
beginning of this process can disappear again, but under appropriate conditions 
may gradually develop Into raised plaques characteristic of atherosclerosis. As 
damage progresses, ulceration can occur resulting in disruption of the 
endothelium, attracting platelets and other blood components which aggravate 
the damage. In addition, small pieces of tissue can become dislodged, thus 
forming the focus for the development of a thrombus.
Under normal circumstances these vulnerable LDL particles would be 
protected by antioxidants, such as vitamin E, leading to decreased production of 
mm-LDL^^ '^^^®'^^\ The lower production of mm-LDL would reduce release of 
lysosomal enzymes and lipids, decrease plaque progression, endothelial 
damage and disturbances of plaque structure. However, when antioxidant
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status is compromised either because of poor dietary intake of these nutrients or 
because of high requirements this protective mechanism will be impaired. The 
susceptibility of the LDL particle to oxidation depends partly on its fatty acid 
composition, partly upon its own antioxidant status (the balance of pro- and 
antioxidants) and also upon its size (small particles are more susceptible). There 
is now increasing evidence that particles enriched by dietary means with 
monounsaturated fatty acids (as opposed to polyunsaturates) are relatively 
resistant to such damage.
It is not clear why there are marked differences in the incidence of 
coronary heart disease between countries but the major risk factors 
(smoking, blood cholesterol and hypertension ) account for only 50 % of its 
occurrence. There Is a view that some factor associated with fruit and vegetable 
intake may help explain some of the remainder.
The acknowledged importance of fruit and vegetables is not new but our 
knowledge of why they are important has been expanding. They collectively 
provided a wide variety of nutrients, with different sub-groups being rich in 
particular nutrients and substances not currently recognised as nutrients, such 
as flavonoids (found In citrus fruit and red wine). A number of these nutrients 
have antioxidant properties and it is on these that particular interest has focused.
Dietary surveys in various countries have shown strong inverse
correlations between mortality and coronary heart disease and the intake of
222fresh fruit/ vegetables and vitamins C, E, and p-carotene 
In the WHO/ MONICA project, which was designed to compare heart disease 
mortality in a number of countries, data have been collected on plasma 
antioxidant levels in middle-aged men from 16 European populations, in which
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the difference in age-specific mortality from coronary heart disease ranged six­
fold. Two of the ‘classical’ risk factors, total plasma cholesterol and blood 
pressure, were found to be only weakly correlated with coronary heart disease
223risk and surprisingly there was no significant correlation with smoking habits 
The authors suggest that the latter finding might be explained by the known 
deleterious effects of smoking balanced in Southern European populations by 
protective dietary factors such as vitamin E. indeed a strong inverse correlation 
was found between plasma vitamin E levels and coronary heart disease, and 
vitamin C showed moderately strong Inverse relationship. Correlations were also 
found for vitamin A but were weaker, and the correlation was weak or absent for
223 224,225p-carotene and selenium . However studies have indicated that 
selenium might be important in reducing heart disease risk, in at least some
circumstances. Furthermore markedly lower selenium levels in patients with
226severe atherosclerosis have been observed compared with controls . In two
227 228major prospective studies, one in men and the other in women , high 
intakes of vitamin E were associated with a reduced incidence of coronary heart 
disease.
The following studies provide inconclusive evidence regarding vitamin E 
and reduction in cardiovascular risk. More than thirty-four thousand post­
menopausal women with no overt cardiovascular disease were followed for 
seven years after completing dietary questionnaires, including information on
229dietary supplements . The risk of death from coronary heart disease was 
lower in those with a higher intake of vitamin E (diet plus supplements), but 
there was little to suggest that vitamin E from the diet had any impact. Vitamin A 
and C intake seemed unimportant in determining heart disease. Although diet 
may be important this study may simply indicate healthy people with a different 
lifestyle rather than being protective In its own right. A recent randomised
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placebo controlled trial of large doses of vitamin E in 2,002 patients with 
coronary heart disease followed for a median of 510 days in the Cambridge 
region (CHAOS), showed a 77 % risk reduction in non-fatal myocardial 
infarction but with a non-significant higher cardiovascular and all cause mortality
230in those taking the vitamin . This trial is encouraging but had insufficient 
power to resolve the disparity between the apparent benefits of myocardial 
infarction but possible adverse affects of death. It also had methodological 
problems in that the vitamin E (d-a-tocopherol) supplements were reduced from 
800 lU/day to
400 lU/day and there was no attempt at randomization between the two vitamin 
E dosage groups. The observation of the CHAOS trial has not been reproduced 
in two larger trials.
The Heart Outcomes Prevention Evaluation (HOPE) Study^®  ^enrolled 
2545 women and 6996 men of 55 years or older who were at high risk for 
cardiovascular events because they had cardiovascular disease or diabetes in 
relation to one other risk factor. 16.2%, randomly assigned, received 400 ID of 
vitamin E daily from natural sources or a matching placebo for 4.5 years. There 
was no significant difference in the number of deaths from cardiovascular 
causes between the supplemented group and the placebo group (relative risk, 
1.05. p = 0.33). This trial concluded that patients who were at high risk for 
cardiovascular events, supplementation with vitamin E had no apparent effect 
on cardiovascular outcomes. The GISSI-Prevenzione trial^ ®^  trial was an open- 
label, randomised study that evaluated the effects of co3 PUFA (polyunsaturated 
fatty acids) and vitamin E on the combined end point of death, nonfatal 
myocardial infarction, and nonfatal stroke in 11,324 male and female patients 
who survived a myocardial infarction within 3 months prior to randomisation. 
Patients were randomised to co3 PUFA 1 g/day, vitamin E 300 mg/day (approx. 
300 lU/day), both o)3 PUPA and vitamin E, or no treatment. Median time 
between suffering the myocardial infarction and being randomized was 16 days,
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and follow-up continued for 3.5 years. The population was relatively low risk; 
only 16% of patients were 70 years of age or older, 14% had an ejection fraction 
below 40% as measured by echocardiogram, and 29% had a positive exercise 
stress test. No significant baseline differences existed between any of the 
treatment groups. Two-way and four-way intent-to-treat analyses evaluating the 
effects of vitamin E supplementation showed vitamin E had no clinically 
significant benefit on the combined end point of all-cause mortality, nonfatal 
myocardial infarction, or nonfatal stroke. When the secondary outcome measure 
of cardiovascular death was analyzed, the four-way analysis showed that the 
vitamin E group had a relative risk of suffering a cardiovascular death of 0.80 
(95% Cl 0.65-0.99) compared with the control group. The relative risk for 
co3 PUFA supplementation group was 0.70 (95% Cl 0.56-0.87) compared to the 
control group and was significantly better than the vitamin E group. When the 
effect of co3 PUPA plus vitamin E was evaluated, the benefits on the combined 
end point and on total mortality were similar to those with co3 PUFA alone. 
Adverse effects led to the discontinuation of the study drug in 3.8% of the œ3 
PUFA patients and 2.1% of the vitamin E patients. The most frequently reported 
reactions for vitamin E were gastrointestinal disturbances (2.9%) and nausea 
(0.4%). Malignancy was diagnosed in 2.2% of the control patients, 2.7% of the 
co3 PUFA patients, and 2.6% of the vitamin E patients during the study.
Evidence for vitamin E supplementation for secondary prevention of myocardial 
damage is not convincing and indeed the MRC/BHF Heart Protection Study^ ®® 
has not been able to demonstrate any benefits from such supplementation. 
Other large-scale randomized trials are currently in progress and still to report. 
Long term follow-up continues in several completed trials.
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Further trials:
1: The trial of vitamin E and aspirin in women is part of the Womans Health 
study, which will end in 2001. This study Is being used to assign 40,000 women 
aged 45 years or older with no history of cardiovascular disease to receive 
vitamin E or placebo and aspirin or placebo. The primary end point will be 
reduction in all major vascular events. The results of the vitamin E 
randomisation for this study have not yet been reported.
2: The Women’s Angiographic Vitamin and Oestrogen (WAVE) trial is designed 
to include 400-450 postmenopausal women aged 75 years or younger with 
angiographically documented coronary vessel occlusion of 15-75%. The four 
treatment groups will receive hormone replacement therapy (HRT) and 
antioxidants (vitamin E and vitamin C), active HRT and anti-oxidant placebo, 
HRT placebo and antioxidants, or HRT placebo and antioxidant placebo. The 
primary end point is angiographic change. Recruitment ended in 1999, and 
subjects will be followed through 2001. The results of this study indicated that 
combination of vitamin E and vitamin C did not retard the progression of 
coronary atherosclerosis over a 2.8-year follow-up among 423 postmenopausal 
women^ ®®®.
3: The Women’s Antioxidant and Cardiovascular Study^ ®®®, which prospectively 
will evaluate the effect of vitamin E, vitamin C, and B-carotene on the risk of 
major cardiovascular events. Recruitment began in 1993. The trial will continue 
until 2002. This study is still ongoing and has not yet reported^®® .^ However, 
because of the factorial design used, it will allow for examination of potential 
Interactions between vitamin E and other antioxidants.
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1.7.2 Schizophrenia
Schizophrenia is probably the most devastating of the psychiatric 
syndromes. Characteristic features include hallucinations, delusions, and bizarre 
behaviour and deterioration from the previous level of occupational and social 
functioning. It is a common disease with a life time prevalence of
0.5 “  The Diagnostic and Statistical Manual of Mental Disorders gives
the current diagnostic criteria for schizophrenia and can be divided into two 
groups which have characteristic symptoms. A schizophrenic can be described 
as having predominantly positive symptoms of thought disorder or delusions or 
hallucinations. Or predominantly negative symptoms of apathy and withdrawn 
behaviour characteristics. Schizophrenia usually occurs in persons with 
significant genetic predisposition to the illness. The concordance rate for 
monozygotic twins has been reported to be between 40 per cent and 65 per cent 
whereas a 10 per cent to 15 per cent rate has been reported in dizygotic 
twins^ ®®. The risk with one affected parent is 5% to 10 %, but it is 45 to 50% if 
both parents have schizophrenia. Adoption studies now document an increased 
risk for the development of schizophrenia in children of schizophrenic patients, 
even if the children are adopted into a healthy family before development of 
schizophrenia in the biologic parents. Rates for development of schizophrenia 
are lower if the child is raised into a psychologically healthy family than an 
unhealthy one, underlining the importance of environment for expression of the 
apparent inherited vulnerability^®®.
The exact mode of inheritance is complex, and most investigators believe 
a polygenic model best fits the data^®^ . Certainly, classic Mendelian models are 
not sufficient. Additionally, since most of those with relatives who have 
schizophrenia do not develop illness, multiple environmental have been 
proposed. These may not be specific but instead involved multiple serious 
insults, including a traumatic environment, exposure to drugs (phencyclidine,
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lysergic acid diethylamide, amphetamines), birth trauma or viral exposure in 
utero.
The pathological mechanisms of this extremely complex syndrome are 
unknown. Certainly the most influential theory hypothesizes excessive dopamine 
activity in the mesolimbic and frontal regions. The potency of almost all of the 
effective antipsychotic agents is highly correlated with the ability to block central 
dopamine activity. Albeit indirect, these observations provide the strongest 
evidence of an etiologic link between schizophrenia and dopamine activity.
There is provocative evidence from positron emission tomography (PET) and 
cerebral blood flow studies that the frontal region in schizophrenics is hypo- 
functional relative to posterior brain regions, perhaps reflecting an injury to 
dorsolateral frontal regions that become manifest in early adulthood. This is also 
consistent with observations of enlarged ventricles in about 30% of patients. 
Post-mortem dopamine receptor binding studies, as well as positron emission 
tomographic dopamine receptor-binding studies, showed increased mesolimbic 
dopamine receptors in schizophrenic patients, even in those who have not 
received the dopamine blocking neuroleptics. Current theories suggest that this 
up-regulation of dopamine receptors could be secondary to decreased inhibition 
of this region by hypofunctional frontal regions. Although these theories have 
been the most productive and consistent areas of research into the 
pathophysiology of schizophrenia, they are considered an incomplete 
explanation of the phenomena involved, and this remains an active area of 
investigation. A membrane phospholipid hypothesis (Horobin (1994))^ ®® has 
been put forward as a more appropriate explanation for the biochemical basis for 
the neurodevelopment concept of schizophrenia and has now become a more 
probable hypothesis for the development of schizophrenia.
Studies showing that polyunsaturated fatty acids (PUFA) of the co3 and co6 
series are depleted in cell membranes of neuroleptic treated schizophrenic 
patients gave first indications that phospholipids may be involved in this disease
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process. Peet et ai showed that schizophrenic patients have a bimodai 
distribution of PUFA and found reduced levels of co6 PUFA which correlated with 
plasma levels of thiobarbituric acid reactive substances (TBARS), suggesting 
that there was increased oxidative breakdown of these PUFA. In schizophrenic 
patients Glen et al found that a group of patients with the lowest red blood 
cell (RBC) membrane levels of 20 and 22 carbon PUFA were those who showed 
predominantly negative symptomatology. Other evidence suggests that 
breakdown of PUFA is increased in schizophrenia. This includes studies using 
magnetic resonance spectroscopy, which have shown decreased levels of 
phosphomonoesters and increased levels of phosphodiesters in the frontal 
cortex of drug free schizophrenic patients, consistent with decreased synthesis 
and/or increased breakdown of membrane phospholipids This index of 
increased phospholipid breakdown correlates with severity of schizophrenic 
symptoms There are two reports that pentane in expired air is significantly 
increased in schizophrenic patients, again consistent with increased oxidative 
breakdown of PUFA 4^3.244
Increased phospholipase activity is one mechanism, which would promote 
increased breakdown of membrane phospholipids. It is therefore of great i
interest that significant elevations of phospholipase A2 (PLA2) have been 
reported in the platelets of schizophrenic patients This report refers to a non­
specific measurement of PLA2 activity . More recently as has been reported 
earlier, levels of type IV cytosolic PLA2 has been shown to be increased in red 
blood cells of patients with schizophrenia^®"'. Arachidonate is released 
selectively by type IVA phopholipase A2 and may therefore modify the 
transmission in dopaminergic synapes (to quote Piomelli (1996) by 
“arachidonate mobilisation and stimulation of the presynaptic metabotropic 
receptors”)^ "'®. There have now been two reports of genetic abnormalities in the 
PLA2 gene of schizophrenic patients. One group has reported a significant 
difference in allele distribution between schizophrenic patients and controls at a
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polymorphic site on the promoter region of the cPLAg gene It is therefore 
possible that a genetically determined abnormality of phospholipase activity is 
responsible for at least in part the depletion of PUFA in cell membranes of 
schizophrenic patients. However the evidence for oxidative damage in this 
condition remains strong.
The phospholipid hypothesis of schizophrenia is able to integrate 
neurodevelopment and receptor based hypotheses and also provides new 
approaches to treatment. A genetically determined predisposition towards 
depletion of membrane levels of PUFA which could be modulated by dietary 
intake in infancy and later life could underlie reported neurodevelopmental 
abnormalities in schizophrenia. In addition, the membrane lipid environment has 
significant effects upon neuroreceptor function and this may underpin the 
efficacy of currently available treatment approaches, which are aimed at 
modulating receptor function
1.7.3 Tardive Dyskinesia
Tardive Dyskinesia (TD) is the name given to a set of abnormal, 
involuntary movements of the orofacial area or extremities. It is thought to result 
from prolonged treatment with neuroleptic medications that help control 
symptoms of severe mental illness, particularly schizophrenia. It literally means 
'late movement disorder’. Although the aetiology is unclear, it has been 
postulated that lipid peroxidation, through the action of free radicals is a possible 
mechanism for neuronal damage in tardive dyskinesia . Clinical evidence 
supporting the view that free radicals are involved in this process include 
elevated levels of lipid peroxidation in the cerebrospinal fluid of dyskinetic 
patients and a possible action of vitamin E on dyskinetic symptoms. Of a 
number of studies, examining the therapeutic effect of vitamin E on Tardive 
Dyskinesia, some but not all have found some benefit 250.251.252
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2 Materials and Methods
2.1 Materials and Subjects
2.1.1 Materials
Names and address of suppliers of reagents, analytical systems, hardware
and software can be found in Appendix 1.
2.1.2 Nutrition Study Subjects and Controls
Subjects in this study group were recruited from:
1. Patients in the all wards of the Victoria Infirmary, Glasgow who had a 
baseline screen for nutritional assessment (January 1994 to December 
2000). As this sample was a baseline level no patient was on either 
enteral or parenteral nutritional support. As these samples were being 
used for nutritional monitoring no ethical permission was required.
2. Patients who were on home enteral nutrition (January 1994 to
December 2000). These patients were either wholly or partly on artificial 
feeding. The enteral feeds contain only the Reference Nutrient Intake 
(RNI) of vitamins and minerals. As these samples were being used for 
nutritional monitoring no ethical permission was required.
3. Patients from two General Practices’, situated in areas of population 
with different deprivation categories based on the Carstairs and 
Morris^®  ^index of deprivation and related to postal code. As these 
samples were being used for lipid/nutritional monitoring no ethical 
permission was required.
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4: Normal control subjects were recruited form the staff of Biochemistry
Department, Victoria Infirmary, Glasgow.
2.1.3 Intensive Care Unit Myocardial Injury Study Subjects.
Patients admitted to the intensive care unit of the Victoria Infirmary, 
Glasgow, had an assessment of myocardial injury by measurement of 
cardiac troponin I throughout their stay in this unit^ ®"^ . Measurements for the 
vitamin levels were undertaken on samples obtained on day 1 of the 
admission of patients from this study group. None of these patients had 
commenced supplementary feeding. The Local Medical Ethics Committee 
approved the original study and deemed informed consent was not required.
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2.1.4 Schizophrenia Study and a Study of Tardive Dyskinesia 
Subjects and Controls
1. Schizophrenia study
a) Patients with schizophrenia, satisfying DSM-III-R criteria^^^ for the 
diagnosis of schizophrenia, were recruited by the Highland Psychiatric 
Research Group, and categorised as having either predominantly positive or 
predominantly negative symptoms. These patients with positive symptoms 
exhibit persistent symptoms of either thought disorder or hallucinations and 
delusions while those with negative symptoms show apathy and withdrawn 
behaviour characteristics. Ethical permission for this study was obtained 
from the ethics committee of Craig Dunain Hospital.
b) A normal control group from the staff of Craig Dunain Hospital, 
Inverness, was also supplied for this study.
2. Tardive Dyskinesia Study
a) Subjects were recruited from the long-term wards of Bellsdyke 
Hospital, Larbert. All patients satisfied DSM-III-R criteria^^^ for schizophrenia 
and had been exposed to antipsychotic medication for a minimum of five 
years. Dyskinetic movements were assessed using a standardized 
procedure employing the Abnormal Involuntary Movement Scale (AIMS) 
Ethical permission for this study was obtained from the ethics committee of 
Bellsdyke Hospital.
b) A normal control group was also recruited from hospital staff for this 
study.
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2.1.5 Statistical Analysis and Methods
All statistical analysis was carried out on Analyse-lt version 1.44 (Analyse-lt 
Software Limited, UK) a data analysis toolkit for Microsoft Excel. All variables 
with >20 observations were assessed for normal distribution using the 
Shapiro-Wilk W test^ ^®, useful for sample sizes up-to 5,000, which is regarded 
as the most powerful statistical test for normality. A coefficient of 1 indicates 
normality and a low p-value indicates the sample is non-normally distributed. 
Non-normally distributed data is shown with the median and inter-quartile 
range and normally distributed data with the mean and standard deviation. For 
completeness of the data tables the mean, standard deviation, median and 
inter-quartile range are shown, although it is appreciated that subsequent 
statistical tests should be applied appropriately. If variables were not normally 
distributed then the Mann-Whitney U test^^  ^was applied. This method formally 
tests for a difference between medians of two independent samples and is also 
commonly referred to as the Wilcoxon rank-sum test. It is regarded as a 
powerful alternative to the independent samples t-test. If variables were 
normally distributed then an independent samples t-test^^^ was applied. This 
method formally tests for a difference between the mean of one sample against 
a hypothesised mean, or between the means of two independent samples. 
Pearson correlation was used to assess an association between 2 related 
varlables^^^. Multiple linear regression analysis is used to predict values for a 
response variable (Y) based on one or more predictor variables^^^.
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2.2 Methods
2.2.1 Vitamin A and vitamin E analysis.
Principle
Vitamins A and E were determined simultaneously by a high pressure liquid 
chromatography (HPLC) technique adapted form a method described by Bieri et
Plasma are mixed with ethanol and internal standard (tocopherol acetate and 
retinol acetate), spun and extracted with hexane. The hexane layer is separated, 
evaporated and reconstituted with methanol.
The extracted sample is injected onto a 150 x 3.2 mm column of Ultracarb 5 \i 
ODS (20) (Phenomenex) with a mobile phase (acetonitrile/methanol, 80/20 by 
volume) running at 1.5 ml/minute. Retinol is monitored at 325 nm and 
a-tocopherol at 292 nm.
Reagents
a-tocopherol, tocopherol acetate, retinol and retinol acetate all HPLC grade, 
were obtained from Sigma Chemical Co. HPLC grade acetonitrile, methanol and 
hexane were obtained from British Drug House (BDH) and absolute alcohol from 
Hayman Ltd.
Chromatography
The high performance liquid chromatography system was an Agilent Technology 
HP 1100 series(Figure 29) comprising:
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HP 1100 System
1. Solvent Cabinet
2. Vacuum Degasser
3 Remote Cable (5061-3378)
4. Pump
5. Autosampler
6. Controller Area Network (CAN) bus cables (5181-1516) included with each HP 1100 module
7. Column Compartment
8. Detector
9. HP 10833B HPIB cable included with HP ChemStation
10. HP ChemStation
11. Centronics cable included with HP ChemStation
12. Printer
Figure 29
2: HP 1100 Series G1322A Vacuum Degasser,
4: HP 1100 Series G1311A Quaternary Pump
5: HP 1100 Series G1313A Autosampler
7: HP 1100 Series G1316A Thermostatted Column Compartment
8: HP 1100 Series G1314A Variable Wavelength Detector.
10: HP ChemStation (HPLC control and integration software)
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The mobile phase was degassed by the vacuum degasser and mixed in a ratio 
of 80/20 volume/volume (acetonitrile/methanol) by the multi-channel gradient 
valve in the quaternary pump. The flow rate was 1.5 mLs per minute. The 
separation was carried out on 30 |il extracts in mobile phase, isocratically, on a 
150 X 3.2 mm column of 5 |i particles of Ultracarb ODS (20) (Phenomenex).
This column was protected by a 30 x 4.3 mm guard column of 5 p particles of 
Ultracarb ODS (20) (Phenomenex). The variable wavelength detector was 
programmed to monitor at 325 nm from zero to 4.5 minutes and at 292 nm from 
4.5 to 10.5 minutes. Retention times for Vitamin A (Retinol) and Vitamin E (a- 
tocopherol) were 1.9 minutes and 8.2 minutes respectively. Retention times for 
the Internal standards retinol acetate and tocopherol acetate were 2.3 minutes 
and 9.5 minutes respectively. ChemStation software monitored the output and 
then integrated the peaks using an internal standard method.
Standard preparation
Stock standards were stored at -20 °C and working standards were prepared 
under natural light and stored at -20°C. Table 4 shows stock concentrations and 
dilutions to produce working standards, formula weights and molar extinction 
coefficients.
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Table 4: Stock and Working Standards
Vitamin Absorbance
Wavelength
(nm)
Formula
Weight
Molar
Extinction
Coefficient
Stock
Concentration
Working
Standard
Dilution
Retinol 324 -325 286.5 52572.75 3.49 mmol/L 125 pt stock + 
25 ml of ethanol
Retinol
Acetate
326 328.8 50917.50 3.04 mmol/L 125 \x\ stock + 
25 mi of ethanol
a-tocopherol 294 430.7 3057.97 4.64 mmol/L 125 111 stock + 
25 ml of ethanol
Tocopherol
acetate
284 472.8 2033.04 4.23 mmol/L 500 ]il stock + 
25 ml of ethanol
Working standard concentrations are calculated by use of the Beer-Lambert 
law, which states that the absorption of light energy at any wavelength is solely 
dependent on the concentration of the absorbing material and the length of the 
light path through the absorbing medium. The equation for this relationship is 
given below:
A = logio^7i = Ecl
Where A = absorbance, Io= intensity of incident light, I = intensity of transmitted light, c = 
concentration, e = molar extinction coefficient and I -  the light path which is usually 1 
centimetre.
Given the extinction coefficient of a substance at a wavelength corresponding to 
maximum absorption, any solution of this substance can have its concentration 
determined by measuring the absorbance of the unknown solution at the same 
wavelength, provided there are no interfering substances present.
Working solutions of retinol and a-tocopherol are scanned over a wavelength 
range (270 nm to 370 nm for retinol and 250 nm to 350 nm for a-tocopherol) on 
a Perkin-Elmer Lamda 5 UV/VIS spectrophotometer blanking with ethanol. Use 
of the above equation allows the concentration of the working standards to be 
determined using the molar extinction coefficient and the maximum absorbance
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obtained on the scan which relates to either retinol or a-tocopherol. You do not 
require to calculate the concentrations of tocopherol acetate or retinol acetate 
as they are used as internal standards. Both tocopherol acetate and retinol 
acetate are added to the same ethanol solution to produce a combined internal 
standard solution.
Sample preparation
200 |i.l of retinol and 200 |al a-tocopherol are mixed with 200 |nl of HPLC 
grade water (BDH) and 200 pi of internal standard solution. 200 pi of plasma are 
mixed with 400 pi of ethanol and 200 pi of internal standard solution. The 
standard/samples are vortex mixed for 1 minute and then 400 pi of hexane is 
added. The standard/samples are vortex mixed for a further 3 minutes and then 
spun at 1500 rpm for 5 minutes. 300 pi of the upper (hexane) layer is removed 
into an eppendorph tube. The hexane is evaporated to dryness using a heating 
block, set at 50 °C, under a stream of oxygen free nitrogen for 2 minutes. The 
standard/samples are reconstituted in 100 pi of methanol and vortexed 
thoroughly for 3 minutes. The sample is then placed into a glass insert in an 
amber via! and sealed with a butyl rubber seal and screw cap. The vial is placed 
on the auto-sampler and 30 pi is injected onto the column. The Ghemstation 
software collects and integrates the data. From the method described above the 
known concentrations of retinol and a-tocopherol standards are typed into the 
calibration table of the Ghemstation software to allow for the calculation of your 
unknown samples. The internal standard allows for extraction variability.
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Quality Control
Each assay run of vitamin analysis has a quality control sample at position 3 
after the two standard vials and every 10^ *^  position thereafter plus one level at 
the end of the run.
Sensitivity
The lowest detectable level of was estimated to be 0.1 pmol/L for 
vitamin A and 1 pmol/L for vitamin E.
Precision:
The precision was assessed using unassayed quality control material form 
Bio-Rad (Lyphocheck Immunoassay controls 1 & 3).
Vitamin A:
Level
(pmol/L)
Within Batch CV 
(n = 10)
Between Batch CV 
(n = 50)
0.44 7.2% 8.8%
1.44 3.8% 8.0%
Vitamin E:
Level
(pmol/L)
Within Batch CV 
(n = 10)
Between Batch CV 
(n = 50)
8 7.0% 9.2%
15 3.1% 6.0%
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2.2.2 Cholesterol analysis 
Principle
Cholesterol esters are hydrolysed by cholesterol esterase to form fatty 
acids and free cholesterol, which is subsequently oxidised to cholestenone and 
hydrogen peroxide by cholesterol oxidase. The hydrogen peroxide is oxidised by 
a peroxidase liberating oxygen which is used in the oxidative condensation of 
phenol and 4-aminophenazone to form 4-(p-benzoquinone-monoimino)- 
phenazone, a red coloured compound, which is measured bichromatically at 
505/70Gnm. Analysis was carried out on the Hitachi 717 clinical chen Jstry 
analyser.
Cholesterol esterase 
Cholesterol esters + H g O ____________________ ^  Cholesterol -î- RCOOH
Cholesterol oxidase 
Cholesterol i  O2 __________________ 4“Cholestr :“niîe -i- H o C h
Peroxidase
H2O2+ 4-amiriophenazone + phenol — ^  4-p-benzo-qulno;ie- ■ . injino-
phenazone + H2O
. e i
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Reagents.
Roche Diagnostics, Kit Catalogue Number: 1489437 10 x 100 mL
Pipes Buffer pH 6.8 75 mmol/L.
Magnesium 10 mmol/L.
4-Aminophenazone 0.15 mmol/L.
Sodium cholate 0.2 mmol/L.
Phenol 4.2 mmol/L.
Fatty acid polyglycolether 0.1%.
Cholesterol esterase 0.5 U/mL.
Cholesterol oxidase >0.15 U/mL.
Peroxidase 0.25 U/mL.
Store at 2-8°C
Standard.
Precipath L: Roche Diagnostics , Catalogue Number: 1285874. 4 x 3  mL. 
Method.
The analyser is calibrated once a week, or as required, using the Precipath L 
standard.
Internal Quality Control
Diagnostics Scotland Low, Mid and High quality control material are analysed 
every day
Method Linearity.
0.08 - 20.7 mmol/L
Sensitivity.
0.08 mmol/L
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Precision
Precision was determined using low, mid and high quality control material 
from Diagnostic Scotland.
Level
(mmol/L)
Within Batch CV 
(n = 10)
Between Batch CV 
(n = 50)
3.9 0.82% 2.7%
5.9 0.93% 2.0%
7.5 0.74% 1.7%
Interference.
Haemoglobin >2g/L.
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2.2.3 Triglyceride analysis 
Principle
Triglycerides are hydrolysed by lipase to glycerol and fatty acids the 
former being converted to glycerol -3- phosphate in the presence of ATP by 
glycerokinase in the first auxiliary reaction. Glycerophosphate oxidase converts 
glycerol -3-phosphate to dihydroxyacetone phosphate with the formation of 
hydrogen peroxide. This hydrogen peroxide is used in the final indicator reaction 
in the oxidative condensation of 4-aminophenazone and 4-chlorophenol via 
peroxidase to form a red coloured compound which is measured bichromatically 
as 4-(p-benzoquinone-monO“imino)-phenazone at 505/700 nm. Analysis was 
carried out on the Hitachi 717 clinical chemistry analyser.
Lipoprotein lipase
Triglycerides + H2O--------------------------------►Glycerol + RCOOH
Glycerol kinase
Glycerol + ATP ---------------------------------► Glycerol-3-Phosphate + ADP
Glycerol phosphate oxidase 
Glycerol-3-Phosphate +O2 -----------------'--------------- ► Dihydroxyacetone phosphate + H2O2
Peroxidase
H2O2 + 4-aminophenazone + 4-chlorophenol--------------------- ^  4-p-benzoquinone-monoimino-
phenazone +2H2O +HCI
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Reagents.
Roche Diagnostics, Kit Catalogue Number; 1488899, 10 x 100 mL 
Reagent:
Pipes buffer pH 6.8 50 mmol/L.
Magnesium sulphate. 40 mmol/L.
Disodium EDTA. 10 mmol/L.
Sododium cholate 0.2 mmol/L.
4-chiorophenol 4.7 mmol/L.
Potassium hexacyanoferrate 1 jimol/L.
Fatty alcohol polyglycolether 0.65%.
Adenosine triphosphate 1.4 mmol/L
4-Aminophenazone 0.13 mmol/L
Lipoprotein lipase 5 U/mL.
Glycerol phosphate Oxidase 2.5 U/mL.
Glycerol kinase 0.19 U/mL.
Peroxidase 0.10 U/mL.
Stable up to expiration date at 2-8°C or 14 days refrigerated on analyser 
opened.
Standard.
Precipath L. Roche Diagnostics, Kit Catalogue Number: 1285874. 4 x 3  mL. 
Method.
The analyser is calibrated once a week, or as required, using the Precipath L 
standard.
Internal Quality Control
Diagnostics Scotland Low, Mid and High quality control material are analysed 
daily.
Linearity
0.05 - 11.4 mmol/L.
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Sensitivity.
0.05 mmol/L 
Precision
Precision was determined using low, mid and high quality control material 
from Diagnostic Scotland.
Level
(mmol/L)
Within Batch CV 
(n = 10)
Between Batch CV 
(n = 50)
1.10 1.18% 2.4%
1.85 0.86% 2.4%
2.73 0.81% 1.8%
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2.2.4 High Density Lipoprotein (HDL) analysis 
Principle
A selective detergent solubilises only HDL, the other lipoproteins (LDL and 
VLDL) and chylomicrons are left inactive against the enzyme reactivity.
Hydrogen peroxide formed is oxidised and the chromogen N, N-bis (4- 
sulphobutyl)-m-toluidine-disodium (DSBmt) combines with 4-aminophenazone in 
an oxidative condensation reaction to form a blue complex proportional to the 
HDL-Cholesterol present and is measured at 600/700nm.
Selective polyanion detergent 
LDL, VLDL, Chylomicrons +HDL ----------------- ► Solubilised HDL
Cholesterol oxidase/ Esterase 
HDL + H2O +02 --------------------------- ► 4- cholestenone + fatty acids +H2O2
Peroxidase
H2O2 + DSBmt   ► Blue chromogen
Reagents.
Bio-Stat, Kit Catalogue Number: 915090 1 x 60 ml, 1 x 20 ml.
Reagent 1
Buffer 30 mmol/L pH 7.0
4-aminophenazone 0.9 mmol/L
Polyanion detergent contains sodium hydroxide 2.8 mg
Reagent 2
Cholesterol esterase 7200 U/L
Cholesterol oxidase 7200 U/L
Chromogen (DSBmt) 1.1 mmol/L
Sodium hydroxide 2.8 mg.
Store at 4'' C.
Standardisation
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Bio Stat calibrator Catalogue Number: 915084. Concentration: 1.4 mmol/L CDC 
referenced.
Store at 2-8 °C. Stable for 7 days after reconstitution at this temperature. 
Method.
Analysis was carried out on the Hitachi 717 clinical chemistry analyser 
along with total cholesterol and triglycerides as part of the lipid profile. The 
analyser calibrated once a week while blanking the reagent daily
Linearity.
0.08 - 3.12 mmol/L 
Internal Quality Control
Diagnostics Scotland Low, Mid and High quality control material are analysed 
daily.
Sensitivity.
0.08 mmol/L 
Precision
Precision was determined using low, mid and high quality control material 
from Diagnostic Scotland.
Level
(mmol/L)
Within Batch CV 
(n = 10)
Between Batch CV 
(n = 50)
1.38 1.3% 3.25%
1.58 1.0% 4.74%
2.21 1.5% 3.63%
Interferences.
Unaffected by bilirubin up to 342 pmol/L, Haemolysis up to 1.6 mmol/L, and 
Triglyceride up to 13.5 mmol/L
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2.2.5 C“Reactive Protein analysis 
Principle
Buffered antigen and specific antibody combine to form an 
immunoturbidmetric solution. Polyethylene glycol was added to increase 
polymerisation with dithioerytritol to minimise interference from Rheumatoid 
Factor by denaturing it. The turbidity is measure bichromatically at 340/700 nm. 
Analysis was carried out on the Hitachi 717 clinical chemistry analyser.
Reagents.
Reagent 1
Dako reaction Buffer. Catalogue Number: S2006. Store at 4°C.
Reagent 2
Dako Rabbit anti-human CRP. Catalogue Number: 00329 Store at 4'" C.
Diluent Buffer Catalogue Number: S2005 Store at 4*^  C.
Dilute exactly 10 ml of antibody (Reagent 2) with 10 ml of dilution buffer and mix
gently to avoid frothing.
Standardisation
Protein Reference Unit (PRU) CRP calibrant SPS-03 175 mg/L WHO 
Referenced. Store at -20^0.
Method.
Analysis was carried out on the Hitachi 717 clinical chemistry analyser.
The analyser is calibrated once a week while blanking the reagent daily
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Linearity.
0 - 1 7 5  mg/L.
Internal Quality Control
SPS-12 (50 mg /L), SPS-13 (10 mg/L). Supplied from the Protein Reference 
Unit.
Store at -20°C 
Reference Range.
0 - 1 0  mg/L
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2.2.6 Cardiac Troponin I Analysis 
Introduction
Cardiac troponin I (cTnl, molecular weight: 24000) is a contractile protein 
exclusively present in the cardiac muscle^ ^®'^ ®°. Troponin I is one of three 
subunits of the troponin complex (l,T,C), which with tropomyosin is bound to 
actin in the thin filament of the myofibril, its physiological role is to inhibit the 
ATPase activity of the actinmyosin complex in the absence of calcium, and 
therefore, to prevent muscular contraction^^L 
Three troponin I tissue isoforms have been identified:
Fast troponin I and slow troponin I with molecular weights of 19800 each, 
expressed in fast twitch and slow twitch skeletal muscle fibers, respectively.
Cardiac troponin I with an N-terminal site having an additional chain of 
31 amino acid residues.
Cardiac troponin I levels in acute myocardial infarction (AMI) exhibit similar rise 
and fall patterns to those found in CK-MB. Cumulative data from several studies 
indicate troponin I levels are detectable (above quoted values for non AMI 
samples) 3-6 hours after the onset of chest pain. Troponin I levels peak at 
approximately 24 in non-thrombolysed AMI patients and 10 to 12 hours in 
thrombolysed patients and can remain elevated for 5-6 days post /\|\/||262,263,264 
Sequencing of cardiac troponin I from mammals has shown important 
differences between the cardiac^®  ^and skeletal^ ®® forms. Skeletal muscle does 
not express cardiac troponin I, either during development or in response to 
stimuli^® .^ No cross reactivity with skeletal troponin I isoforms allows distinction 
between cardiac and skeletal injuries, and allows diagnosis of myocardial
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infarction even when associated with muscle lesions (rhabdomyolysis, 
polytraumatism) 264,267.268,269
Cardiac troponin I appears to be particularly useful in the following areas: 
Exclusion/confirmation of myocardial infarction.
Risk assessment of patients with unstable angina pectoris and diagnosis 
of microinfarcts.
Monitoring of the outcome of thrombolytic therapy.
Diagnosis of pan-operative myocardial damage (Coronary artery bypass 
grafting, angioplasty).
Diagnosis of rejection in heterotropic cardiac transplantation.
Principle
The Beckman Coulter Access troponin I assay is an immunoenzymatic 
(“sandwich”) assay. A sample is added to a reaction vessel along with 
monoclonal anti-cardiac troponin I antibody conjugated to alkaline phosphatase 
and paramagnetic particles coated with monoclonal anti-cardiac troponin I 
antibody. The human cardiac troponin I binds to the anti-cardiac troponin I 
antibody on the solid phase, while the anti-cardiac troponin I antibody-alkaline 
phosphatase conjugate reacts with different antigenic sites on the cardiac 
troponin I molecules. After the incubation, the separation in a magnetic field and 
washing removes material not bound to the solid phase. A chemiluminescent 
substrate, Lumi-Phos 530, is added and the light generated by its reaction with 
the captured alkaline phosphatase is measured with a luminometer. The photon 
production is proportional to the amount of enzyme conjugate present at the end 
of the reaction, and therefore, to the concentration of cardiac troponin I in the 
sample. The amount of analyte in the sample is determined by means of a 
stored, multi-point calibration curve.
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Reagents
Beckman Coulter (UK), Catalogue Number: 33320: 100 determinations, 2 
packs, 50 tests/pack
A pack is stable until the expiration date stated on the label when stored at 2 to 
10°C. After initial use, the pack is stable at 2 to 10°C for 28 days.
Beckman Coulter Access Troponin I Reagent Pack: R1
Ria: Paramagnetic particles coated with mouse monoclonal anti-human
cardiac troponin I suspended in TRIS-NaCI buffer, with bovine serum 
albumin (BSA), 0.05% sodium azide.
Rib; O.INNaOH 
R1c: 0.08 M succinic acid
Rid: Purified mouse immunoglobulins, in TRIS-NaCI buffer, with <0.1%
sodium azide, 0.06% ProClin** 300.
Rie: Conjugate: Mouse monoclonal anti-human cardiac troponin I coupled to
alkaline phosphatase in TRIS-NaCI buffer, with BSA, and <0.1% sodium 
azide.
Patient Sample
Serum samples collected with Becton Dickson separator gel tubes were 
used for this assay. Fifty (50) [i\ of sample is used for each determination. 
Samples containing up to 110 mg/l bilirubin, 500 lU/L heparin, 50,000 lU/L 
streptokinase, lipaemic samples containing the equivalent of 6 g/L triglycerides 
and haemolysed samples containing up to 5 g/L haemoglobin do not affect the 
concentration of cardiac troponin I assayed.
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Quality Control
Beckman Coulter catalogue Number: 33329, Access Troponin I QC: 
2.5 ml/vial. 6 x lyophilized vials, 3 levels.
2 X QC1 : Human cardiac troponin I at a level of approximately 0.25 |ig/L in 
buffered human serum matrix containingO.1 % Kathon.
2 X QC2: Human cardiac troponin I at a level of approximately 5 juig/L in buffered 
human serum matrix containing 0.1% Kathon.
2 X QC3: Human cardiac troponin I at a level of approximately 25 |xg/L in 
buffered human serum matrix containing 0.1% Kathon.
Each level is assayed once a day.
Sensitivity
0.03 |xg/L 
Precision
Precision was determined using quality control material from Beckman Coulter 
as described above.
Level Within Batch CV Between Batch CV
W /L) (n = 10) (n = 50)
0.25 5.4% 7.0%
5.0 3.0% 5.1%
25.0 3.4% 6.1%
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Calibrators
Beckman Coulter Access Troponin I Calibrators: catalogue Number:33325,
1 ml/vial. Lyophilized.
SO: Buffered human serum matrix with 0.1% Kathon. Contains 0.0 |ig/l human 
cardiac troponin I.
SI. S2, S3, 54, S5: Human cardiac troponin I at levels of approximately 0.1, 0.5, 
2, 10 and 50 jig/L, respectively, in buffered human serum matrix with 0.1% 
Kathon.
Details of Calibration
An active calibration curve is required for all tests. For the Troponin I assay, 
calibration is required every 28 days to maintain an active calibration curve
Results
Patient test results are calculated automatically by the system software using a 
smoothing spline curve math model. The amount of analyte in the sample is 
determined from the measured light production by means of the stored 
calibration curve.
Limitations of the Procedure
1. Samples can be accurately measured within the reportable range of the 
lower limit of detection and the highest calibrator value (approximately 
0.03—50 ng/ml (jig/1)). If a sample contains more troponin I than the 
stated value of the 85 calibrator, report the result as greater than that 
value. Alternatively, dilute one volume of sample with an equal volume of 
Access Troponin I diluent.
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2. Human anti-mouse antibodies (HAMA) may be present in samples from 
patients who have received immunotherapy^^°’^ ^^ This assay has been 
specifically formulated to minimize the effect of these antibodies on the 
assay. However, carefully evaluate results from patients known to have 
received such therapy or known to contain other heterophilic antibodies.
3. The Access Troponin I assay has no discernible “hook effect” up to 
600 pg/L.
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3 Studies: Outline of Studies, Results and Discussion. 
3.1 Vitamins A and E In Nutrition Studies
3.1.1 Introduction 
Studies have shown that 50% of patients (recruited from five disciplines - 
general surgery, general medicine, respiratory medicine, orthopaedic surgery 
and medicine for the elderly) are malnourished on admission to hospital and 
may deteriorate during their stay^^ .^ Patients who are undernourished are more 
likely to have complications of their illness^^^, have prolonged wound healing^ "^  ^
and take longer to recover and to be discharged from hospitaP^^. Patients In 
this study who require either parenteral or enteral nutritional support are more 
likely to have deficiencies of important antioxidants as well as being subject to 
possible increased levels of free radical damage. In order to balance their 
nutritional deficiencies and maintain their nutritional status macronutrients are 
given as well as micronutrients such as retinol, vitamin E, glutathione and 
selenium. The antioxidant effects of such micronutrients, described earlier 
should afford protection against further free radical cellular damage.
As heart disease is the overall major cause of death in Scotland with the 
Greater Glasgow Health Board area showing one of the highest standardised 
mortality ratio (SMR) for ischaemic heart disease at 127 (Data supplied by the 
Registrar General for Scotland, the Office for National Statistics and the 
Governments Actuary’s Department) in areas of highest deprivation. In 1998 
Gordon McLaren and Marion Bain published a report (Deprivation and Health in 
Scotland -  Insights form NHS Data), which provided an overview of the 
relationship between material deprivation and health in Scotland. In the 
introduction to this report the Chief Medical Officer for Scotland voiced particular
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concern as to the differences in levels of health between the most affluent and 
most deprived. Coronary heart disease was highlighted, as mortality rates form 
acute myocardial infarction (AMI) in those under 65 are higher in those from 
more deprived areas. Because of this finding subjects from two general 
practices, in different areas of deprivation category, are also assessed.
3.1.2 Objectives
The objectives of this study were to measure vitamin E a lipid antioxidant 
and vitamin A to assess adequacy of status. In assessing subjects’ vitamin 
levels a range of hospital ward environments were selected, general wards, high 
dependency and intensive care units in the Victoria Infirmary that reflect severity 
of illness of the subject. It was hoped to assess whether severity of illness 
(possible low antioxidant status and elevated free radical production) would 
show different, degrees of depletion of vitamin E. C-reactive protein^^®, an acute 
phase protein produced by the liver, was also measured in the general ward, 
nutritional support and ICU patient groups as the acute phase is known to 
reduce the cholesterol content in both low and high-density lipoproteins^^^. 
Subjects from two general practices in areas of Glasgow of differing deprivation 
category based on postal code were studied. The deprivation category 
assessed by Carstairs and Morris^®  ^were as follows: For Glasgow post code 
G45 -  deprivation category 7, G73 -  deprivation category 6, G44 - deprivation 
category 2, and G76 -deprivation category 1. deprivation category 7 being the 
most deprived and deprivation category 1 the least deprived. The standardised 
mortality ratio (SMR) reported in the year 1999 (males and females 0 - 6 4  
years), as assessed by postal code, were as follows: G45 -  127, G73 -  118, 
G44 -  83 and G76 -  83 . These patients also had their vitamin levels measured 
to compare them against each area and against the ward subjects. It was hoped 
to assess whether there is a difference in levels in the general population and 
the hospital population.
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3.1.3 Reference Ranges
Normal ranges were calculated from data obtained from the normal control 
group (Table 7). The traditional method of describing a reference range, shown 
below, was used as the vitamin E and vitamin A in this group were normally 
distributed (Table 6) and is sufficiently consistent with textbook ranges (Tietz, 
Clinical Chemistry, second edition 1994), vitamin E: 1 2 - 4 6  pmol/L and 
vitamin A: 1.05 -  2.8 pmol/L
Reference range: Mean ± 1.96 standard deviations, which encompasses 95% of 
the reference sample.
Vitamin A: 1.06 -  3.74 pmol/L
Vitamin E: 1 3 - 5 2  jimol/L
As discussed in section 1.4.2 vitamin E is transported in the plasma 
within lipoproteins and varies with total lipid. In line with other researchers the 
vitamin E has been corrected for cholesterol and triglyceride. However as 
vitamin E is predominantly transported within LDL and HDL the vitamin E has 
also been corrected for cholesterol alone. The vitamin E/cholesterol ratio is 
normally distributed in control subjects therefore the above method was used to 
calculated a normal range. However the vitamin E/(cholesterol +triglyceride) 
ratio is non-normally distributed (table 6) therefore the median and inter-quartile 
range is used.
Reference Range:
Vitamin E/(Cholesterol + Triglyceride) Ratio: 3.46 -  6.06
Vitamin E/Cholesterol Ratio: 3.01 -9 .17
Sex Difference:
Using the larger general practice study group there was no statistically 
significant difference of vitamin E, lipid corrected vitamin E or cholesterol 
corrected vitamin E between males and females. However males appeared to
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have a slightly higher vitamin A level than females (p=0.04).
In the clinical context, with cholesterol measurements it is preferable to consider 
‘action limits’ for primary and secondary prevention and for patients ‘at risk’. ‘At 
risk’ groups defined those at high risk (approximately 3% per year) of a coronary 
event -  non-fatal Ml or coronary death. These current guidelines have been 
adopted by Greater Glasgow Health Board.
The following give details of ‘at risk’ patients:
• Men aged 55 to 74 who smoke and are hypertensive.
• Men or women who are diabetic (<75 years).
• Men or women (<75 years) with a strong family history of coronary heart 
disease (CHD).
• Men or women (<75 years) with evidence of atherosclerotic disease. -  
e.g. intermittent claudication, peripheral vascular disease.
• Strong family history of hyperlipidaemia.
The following action limits which depend on risk status are currently in use.
Primary Prevention action limits:
Cholesterol: Men >8.0 mmol/L, Women >9.0 mmol/L 
Secondary Prevention action limits (Men and Women):
Cholesterol: >5.0 mmol/L 
‘At risk' (Men and Women)
Cholesterol: >5.5 mmol/L 
Other Reference values:
HDL-cholesterol: Men >1.0 mmol/L, Females >1.1 mmol/L 
Triglyceride: <2.3 mmol/L.
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3.1.4 Results
Statistical Analysis of Data from Nutrition Studies
The demographic details of the subjects studied in the six groups are 
summarised in table 5.
Table 5: Demographic Details
Normal
Controls
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
GP
Patients
N 26 540 70 186 171 99
Sex
(M/F)
16/10 301/239 35/35 101/85 92/79 52/47
Mean
Age
45.4 [12.0] 63.3 [17.0] 62.7 [15.7] 61.0 [16.4] 54.4 [12.6] 53.2 [14.3]
Age
Range
22 to 64 15 to 99 17 to 89 15 to 85 27 to 80 17 to 79
Mean + [Standard Deviation]
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The results for the Shapiro-Wilk W tests non-normality for all parameters studied in each 
subject group are summarised in table 6.
Table 6: Shapiro-Wilk W Test for Non-normalitv
Normal
Controls
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
GP Patients
Vitamin A 0.9398 
p: NS
0.9157
p: <0.0001
0.7960
p; <0.0001
0.8660 
p: <0.0001
0.9542
p: <0.0001
0.9558
p: 0.0022
Vitamin E 0.9616 
p: NS
0.8639
p: <0.0001
0.9415 
p: 0.0027
0.9192
p: <0.0001
0.9677 
p: 0.0005
0.9596 
p: 0.0040
Cholesterol 0.9113 
p: 0.0283
0.9580
p: <0.0001
0.9613 
p: 0.0316
0.9708 
p: 0.0007
0.9822 
p: 0.0271
0.9818 
p; NS
T riglyceride 0.8858 
p: 0.0077
0.8656
p: <0.0001
0.7232
p: <0.0001
0.8012 
p: <0.0001
0.8264
p: <0.0001
0.8012 
p: <0.0001
HDL-
Cholesterol
0.9072
p: 0.0228
0.9670
p: <0.0001
0.9671 
p: NS
0.9119
p: <0.0001
0.8740
p: <0.0001
0.9721 
p: 0.0484
Vitamin E/ 
Lipid Ratio
0.9079 
p: 0.0236
0.9527
p: <0.0001
0.9685 
p: NS
0.9913 
p: NS
0.9771
p: 0.006
0.9691 
p: NS
Vitamin E/ 
Cholesterol 
Ratio
0.9277 
p: NS
0.9177
p: <0.0001
0.9475 
p: 0.0058
0.9481
p: <0.0001
0.8738
p: <0.0001
0.9519 
p: 0.0014
C-reactive
Protein
NA 0.9440
p: 0.006
0.9660 
p: 0.7947
0.9944 
p: 0.09988
0.5661
p: <0.0001
NA
Table shows Shapiro-Wilk Coefficient and p value.
A p value < 0.05 indicates significant non-normality of distribution
As expected patient groups show non-normality of distribution for the above analysis. 
See section 2.1.5 for the application of appropriate statistical tests.
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The measurements made in plasma in these nutritional studies are 
presented in table 7 as mean + standard deviation as well as the median + 
interquartile range. The vitamin E/lipid ratio is expresses as pmol of vitamin E per 
mmol of cholesterol and triglyceride in plasma. The vitamin E/cholesterol ratio is 
expressed as pmol of vitamin E per mmol of cholesterol in plasma.
Table 7: Vitamin. Lipid and CRP Levels
Normal
Controls
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
GP Patients
Vitamin A 
(pmol/L)
2.40 [0.68] 
2.33 [1.12]
1.25 [0.69] 
1.17 [0.84]
0.84 [0.49] 
0.71 [0.34]
0.84 [0.48] 
0.74 [0.54]
2.02 [0.82] 
1.88 [1.05]
2.55 [0.84] 
2.50 [1.02]
Vitamin E 
(nmol/L)
32.6 [12.4] 
31.5 [13.5]
26.3 [12.5] 
24.0 [12.0]
20.2 [7.4] 
19.0 [9.0]
17.7 [9.58] 
16.0 [12.8]
35.0 [17.4]
36.0 [30.0]
44.2 [15.7] 
38.4 [21.1]
Cholesterol
(mmol/L)
5.28 [1.16] 
5.45 [1.67]
3.78 [1.28] 
3.60 [1.60]
2.93 [0.93] 
2.95 [1.50]
2.38 [0.98] 
2.30 [1.30]
4.18 [1.26] 
4.30 [1.80]
5.90 [1.39] 
5.80 [2.10]
Triglyceride
(mmol/L)
1.66 [1.10] 
1.22 [1.61]
1.48 [0.80] 
1.31 [0.91]
1.52 [0.92] 
1.40 [0.88]
1.57 [1.12] 
1.32 [1.16]
1.47 [0.81] 
1.35 [0.81]
1.96 [1.16] 
1.69 [1.26]
HDL-
Cholesterol
(mmol/L)
1.36 [0.42] 
1.24 [0.56]
0.96 [0.41] 
0.90 [0.50]
0.80 [0.36] 
0.80 [0.40]
0.64 [0.40] 
0.60 [0.60]
1.28 [0.40] 
1.20 [0.40]
1.26 [0.33] 
1.20 [0.40]
CRP
(mg/L)
LAB 88.7 [65] 
78 [95]
206 [91] 
204 [76.5]
186 [81] 
184 [107]
35.7 [63.5] 
13 [42.5]
NA
Vitamin E/ 
Lipid Ratio 
(umol/mmol)
4.73 [1.19] 
4.76 [1.30]
5.09 [1.85] 
4.81 [2.11]
4.58 [1.32] 
4.50 [1.56]
4.54 [1.53] 
4.45 [1.96]
6.12 [2.37] 
6.44 [3.10]
5.26 [1.24] 
5.23 [1.33]
Vitamin E l  
Cholesterol 
Ratio 
(umol/mmol)
6.09 [1.57] 
6.08 [1.56]
7.14 [2.72]
6.59 [3.11]
7.04 [2.15] 
6.86 [2.31]
7.56 [2.58] 
7.43 [2.86]
8.46 [4.10] 
8.26 [4.02]
6.96 [1.80] 
6.67 [2.10]
Mean+ [Standard Deviation] and Median + [Inter-quartile range]
The above data was presented as patient groups show non-normality of distribution.
No C-reactive protein analysis were carried out on the normal control group or the GP 
patient group.
LAB: For comparison of data the laboratory’s normal reference range was used 
(up to10 mg/L).
Page 104
Table 8: Correlation Between Vitamin E and Cholesterol
Subject Groups Pearson Correlation 
r. p.
Normal Controls 0.73 [0.48-0.87] <0.0001
Ward Patients 0.52 [0.45 -  0.58] <0.0001
High Dependency Unit 0.53 [0.33-0.68] <0.0001
Intensive Care Unit 0.73 [0.66-0.79] <0.0001
Home Nutrition Patients 0.58 [0.47 -  0.67] <0.0001
GP Patients 0.73 [0.62-0.81] <0.0001
Number in brackets represents 95% Confidence Interval
Table 9: Correlation Between Vitamin E and Triglyceride.
Subject Groups Pearson Correlation
r. P-
Normal Controls 0.53 [0.18 to 0.76] 0.0051
Ward Patients 0.37 [0.29 to 0.44] <0.0001
High Dependency Unit 0.15 [-0.09 to 0.38] NS
Intensive Care Unit -0.23 [-0.37 to -0.09] <0.0001
Home Nutrition Patients 0.50 [0.38 to 0.60] <0.0001
GP Patients 0.59 [0.44 to 0.70] <0.0001
Number in brackets represents 95% Confidence Interval
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Table 10: Correlation Between Cholesterol and CRP
Subject Groups Pearson Correlation 
r. p.
Ward Patients -0.39 [-0.55 to -0.20] 0.0002
High Dependency Unit -0.12 [-0.60 to -0.42] 0.6686
Intensive Care Unit -0.14 [-0.47 to 0.23] 0.4652
Home Nutrition Patients -0.07 [-0.42 to 0.30] 0.7138
Number in brackets represents 95% Confidence Interval
Table 11: Statistical Analysis (Mann-Whltnev) CRP 
Nutrition Study
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients
High Dependency 
Unit
<0.0001 T
Intensive Care Unit <0.0001 Î NS
Home Nutrition 
Patients
<0.0001 i <0.0001 i <0.0001
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
Table should be read left to right. E.g.: The HDU subjects have a significantly higher CRP levels than the 
ward subjects.
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Table 12: Statistical Analysis (Mann-Whitnev) Vitamin A
Nutrition Study
Normal
Controls
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients <0.0001 i
High Dependency 
Unit
<0.0001 i <0.0001 i
Intensive Care Unit <0.0001 i <0.0001 i NS
Home Nutrition 
Patients
0.0098 i <0.0001 Î <0.0001 Î <0.0001 Î
GP Patients NS <0.0001 T <0.0001 T <0.0001 Î <0.0001 T
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
Table should be read left to right. E.g.; The ward subjects have a significantly lower Vitamin A than the 
normal control group.
Table 13: Statistical Analysis (Mann-Whitney) Vitamin E
Nutrition Study
Normal
Controls
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients 0.0035 I
High Dependency 
Unit
<0.0001 1 <0.0001 i
Intensive Care 
Unit
<0.0001 i <0.0001 i 0.0100 1
Home Nutrition 
Patients
NS <0.0001 Î <0.0001 T <0.0001 Î
GP Patients 0.0113 Î <0.0001 Î <0.0001 Î <0.0001 Î 0.0112 Î
NS = Not statistically significant T Significantly higher. i  Significantly lower
Table should be read left to right. E.g.: The ward subjects have a significantly lower Vitamin E than the 
normal control group.
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Table 14: Statistical Analysis (Mann-WhitnevV. Cholesterol
Nutrition Study
Normal
Controls
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients <0.0001 si
High Dependency 
Unit
<0.0001 si <0.0001 si
Intensive Care 
Unit
<0.0001 si <0.0001 si <0.0001 si
Home Nutrition 
Patients
<0.0001 si <0.0001 T <0.0001 T <0.0001 T
GP Patients 0.0605 <0.0001 Î <0.0001 Î <0.0001 Î <0.0001 Î
NS = Not statistically significant TSignificantly Higher. si Significantly lower
Table should be read left to right. E.g.: The ward subjects have a significantly lower cholesterol than the 
normal control group.
Table 15: Statistical Analysis (Mann-Whitney): Triglyceride
Nutrition Study
Normal
Controls
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients NS
High Dependency 
Unit
NS NS
Intensive Care 
Unit
NS NS NS
Home Nutrition 
Patients
NS NS NS NS
GP Patients NS <0.0001 T 0.0157 T 0.0011 Î 0.0003 Î
NS = Not statistically significant TSignificantly Higher. si Significantly lower
Table should be read left to right. E.g.: There is no statistically significant difference in triglyceride levels 
between ward patients and the normal control group.
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Table 16: Statistical Analysis (Mann-Whitnev): HDL-Cholesterol
Nutrition Study
Normal
Controls
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients <0.0001 si
High Dependency 
Unit
<0.0001 si 0.0025 si
Intensive Care 
Unit
<0.0001 si <0.0001 i 0.0021 si
Home Nutrition 
Patients
NS <0.0001 Î <0.0001 T <0.0001 T
GP Patients NS <0.0001 T <0.0001 Î <0.0001 T NS
NS = Not statistically significant TSignificantly Higher. si Significantly lower
Table should be read left to right. E.g.: The ward subjects have a significantly lower HDL-cholesterol than 
the normal control group.
Table 17: Statistical Analysis (Mann-Whitney)
Vitamin El Lipid (Cholesterol + Triqiyceridel Ratio: Nutrition Study
Normal
Controls
Ward
Patients
High Dependency 
Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients NS
High Dependency 
Unit
NS 0.0354 si
Intensive Care Unit NS 0.0016 i NS
Home Nutrition 
Patients
0.0014 T <0.0001 T <0.0001 Î <0.0001 T
GP Patients 0.0262 T 0.0520 0.0003 T <0.0001 T 0.0002 si
NS = Not statistically significant TSignificantly Higher. si Significantly lower
Table should be read left to right. E.g.: High dependency unit subjects have a significantly lower Vitamin 
E/lipid ratio than the ward patient group.
Page 109
Table 18: Statistical Analysis (Mann-Whitnev)
Vitamin E/ Cholesterol Ratio: Nutrition Study
Normal
Controls
Ward Patients High 
Dependency Unit
Intensive Care 
Unit
Home
Nutrition
Patients
Ward Patients <0.0001 Î
High
Dependency
Unit
<0.0001 Î NS
Intensive Care 
Unit
<0.0001 Î 0.0134 T NS
Home Nutrition 
Patients
0.0098 Î <0.0001 T 0.0035 Î 0.0240 t
GP Patients 0.0221 Î NS NS 0.0337 si 0.0006 si
NS = Not statistically significant T Significantly Higher. i  Significantly lower
Table should be read left to right. E.g.: The ward patient subjects have a significantly higher Vitamin 
E/cholesterol ratio than the normal control group.
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Table 19: GP Data: Patients of Known Deprivation Category
Normal Controls GP Patients 
Dep. Cat 1 & 2
GP Patients 
Dep. Cat 6 & 7
n. 26 50 25
Mean Age 45.5 [12.0] 54.9 [11.4] 51.2 [13.8]
Sex (M/F) 16/10 31/19 9/16
Age Range 22 to 64 26 to 75 32 to 73
Vitamin A 
(umol/L)
2.40 [0.68] 
2.33 [1.12]
2.79 [0.82] 
2.66 [0.66]
2.49 [0.62] 
2.42 [0.90]
Vitamin E 
(pmol/L)
32.6 [12.4] 
31.5 [13.5]
45.4 [16.4] 
41.8 [23.3]
42.5 [13.9] 
37.9 [19.5]
Cholesterol
(mmol/L)
5.28 [1.16] 
5.45 [1.67]
6.29 [1.33]
6.30 [1.68]
5.93 [1.23] 
6.00 [2.10]
Triglyceride
(mmol/L)
1.66 [1.10] 
1.22 [1.61]
2.10 [1.16] 
1.86 [1.26]
2.34 [1.40] 
2.28 [1.87]
HDL-Cholesterol
(mmol/L)
1.36 [0.42] 
1.24 [0.56]
1.29 [0.38] 
1.25 [0.43]
1.17 [0.28] 
1.10 [0.40]
Vitamin E/ Lipid 
Ratio
4.73 [1.19] 
4.76 [1.30]
5.37 [1.30] 
5.02 [1.26]
5.18 [1.10] 
5.54 [1.21]
Vitamin E/ 
Cholesterol Ratio
6.09 [1.57] 
6.08 [1.56]
7.16 [2.02] 
6.46 [2.55]
7.12 [1.56] 
7.22 [1.72]
Mean Levels + [Standard Deviation] and Median + [Inter-quartile Range]
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Table 20 compares the results found in subjects from least deprived areas 
(Dep. Cat. 1 & 2) with the other nutrition study groups including subjects from 
the most deprived areas ( Dep. Cat. 6 & 7).
Table 20: Statistical AnalvsistMann-Whitnev)
GP Patients of deprivation cateoorv 1 & 2 compared to all other nutrition studv groups.
Vs. Normal
Controls
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
GP Patients 
Deprivation 
Cat. 6 & 7
Vitamin A 
(pmol/L)
NS <0.0001 T <0.0001 T <0.0001 T <0.0001 T NS
Vitamin E 
(fimol/L)
0.0008 T <0.0001 T <0.0001 T <0.0001 Î 0.0012 Î NS
Cholesterol
(mmol/L)
0.0032 Î <0.0001 Î <0.0001 t <0.0001 Î <0.0001 Î NS
Triglyceride
(mmol/L)
0.0469 T <0.0001 T 0.0030 Î 0.0006 Î <0.0001 Î NS
HDL-
Cholesterol
(mmol/L)
NS <0.0001 T <0.0001 T <0.0001 Î NS NS
Vitamin E/ 
Lipid Ratio
0.0285 Î NS 0.0015 Î 0.0006 Î 0.0118 i NS
Vitamin E/ 
Cholesterol 
Ratio
0.0375 T NS NS NS 0.0265 i NS
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
E.g.; GP subjects of deprivation categories 1 & 2 have a significantly higher Vitamin A level than the ward 
patient subjects
There is no significant difference in any of the parameters between deprivation 
categories 1 & 2 and deprivation categories 6 & 7.
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Table 21 compares the results found in subjects from most deprived areas 
(Dep. Cat. 6 & 7) with the other nutrition study groups including subjects from 
the least deprived areas (Dep. Cat. 1 & 2).
Table 21: Statistical Analvsis(Mann-Whitnevl:GP Patients
GP Patients of deprivation cateoorv 6 & 7 compared to all other nutrition studv aroups.
Vs. Normal
Controls
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
GP Patients 
Deprivation 
Cat. 1 & 2
Vitamin A 
(pmol/L)
NS <0.0001 T <0.0001 T <0.0001 Î 0.0017 Î NS
Vitamin E 
(pmol/L)
0.0115 t <0.0001 T <0.0001 Î <0.0001 T 0.0424 Î NS
Cholesterol
(mmol/L)
NS <0.0001 T <0.0001 Î <0.0001 T <0.0001 T NS
Triglyceride
(mmol/L)
0.0373 T 0.0013 T 0.0078 T 0.0025 Î 0.0014 Î NS
HDL-
Cholesterol
(mmol/L)
NS 0.0018 Î <0.0001 T <0.0001 Î NS NS
Vitamin E l  
Lipid Ratio
0.0438 Î NS 0.0051 T 0.0120 T 0.0125 i NS
Vitamin E/ 
Cholesterol 
Ratio
0.0053 Î NS NS NS 0.0697 NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
E.g.: GP subjects of deprivation categories 6 & 7 have a significantly higher Vitamin A level than the ward 
patient subjects.
There is no significant difference in any of the parameters between deprivation 
categories 1 & 2 and deprivation categories 6 & 7.
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3.1.5 Discussion
The vitamin A measurements were included to reflect the plasma status of 
another fat soluble vitamin in the groups studied. The order of decreasing mean 
or median level of vitamin A (table 7) for these groups were:
GP Subjects >Control Subjects >Home Nutrition Subjects >Ward Subjects >High Dependency 
Unit Subjects and Intensive Care Unit Subjects
This order matches the intuitive expectations of the likely nutritional status 
for these subject groups. The position of the home nutrition group reflects and is 
indeed a tribute to the success of their dietary manipulation. However caution 
should be applied to these data as a plasma level is not an assessment of whole 
body stores and interpretation of levels may also be complicated by co-existing 
liver disease and acute phase response. Indeed only a few patients in the ICU 
and HDU groups showed basal values of < 0.7 pmol/L, a level that has previously 
been used to assess vitamin A deficiency.
The order of decreasing mean or median level of cholesterol and HDL- 
cholesterol (table 7) for the six groups were:
Cholesterol:
GP Subjects >Control Subjects >Home Nutrition Subjects >Ward Subjects >Hlgh Dependency 
Unit Subjects > Intensive Care Unit Subjects
HDL-Cholesterol:
Control Subjects > GP Subjects >Home Nutrition Subjects >Ward Subjects >High Dependency 
Unit Subjects > Intensive Care Unit Subjects
The plasma samples from GP subjects were stated to be fasting samples, 
however the triglyceride is only higher in this group and this finding may be due to 
possible dietary effects or non-fasting.
It was not anticipated that the level of plasma vitamin E found in the six 
subject groups would follow so closely the cholesterol levels with correlations
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foremany of the groups as high as r = 0.73. This close correlation suggests some 
form of homeostatic mechanism in the LDL particle to retain vitamin E within the 
LDL particle.
As has been previously discussed there is a clear correlation (Table 8) between 
plasma cholesterol and plasma vitamin E but the correlation between triglyceride 
and vitamin E (Table 9) is not as close. Some vitamin E cholesterol correlation 
was expected as vitamin E is transported in the blood mainly in LDL. The 
correlation coefficient is maximal (0.73) in normal controls and GP subjects and 
lowest (0.52) in ward patients. The correlation between vitamin E and cholesterol 
in intensive care unit patients, which remains at 0.73 is surprising. This despite 
the low levels of cholesterol found in the plasma of these subjects. The median 
cholesterol of 2.30 mmol/L for intensive care patients (Table 7) is significantly 
lower (Table 14) than the 5.45 mmol/L median found in control subjects. This 
observation challenges the convention that vitamin E depletion can best be found 
by examining the vitamin E/cholesterol ratio or even vitamin E/lipid 
(Cholesterol+Triglyceride) ratio in plasma. The vitamin E/Cholesterol ratio median 
of 7.43 found for the intensive care subject group is the highest found in all our 
subject groups, barring the home nutrition patients who all receive 
supplementation, at RNI level, in their feeding regimen. The intensive care unit 
subjects, who had been expected to be most challenged in terms of free radical 
exposure, show no lipid corrected vitamin E deficiency. This striking finding is 
possibly due to the effects of acute phase response on lowering cholesterol 
content in LDL and HDL. This cholesterol lowering results either from increased 
catabolism of cholesterol-rich lipoproteins, or the sequestration and retention of 
LDL in the endothelial spaces^^^.
Table 10 indicates that there is a negative correlation between CRP and 
cholesterol. Figures 30,31 and 32 show multiple linear regression analysis of 
results from ward patients, acute ill patients in ICU and HDU and nutrition patients 
respectively. This statistical analysis is used to assess whether the acute phase
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response, as indicated by CRP, has any significant effect when correlating vitamin 
E and cholesterol.
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Figure 30: Multiple Linear Regression. Vitamin E vs. Cholesterol and CRP
Ward Patients
40 n
35 ■
_I 30 -
oF 25 -=t
UJ 20 -c
Ere 15 -
d 10 -
5
0 -
o
8
<9
10 20
Predicted Y
30 40
Cholesterol: p <0.0001; CRP: p 0.0104 
Figure 31: Multiple Linear Regression. Vitamin E vs. Cholesterol and CRP 
Acutely III Patients (HDU and ICU)
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Figure 32: Multiple Linear Regression. Vitamin E vs. Cholesterol and CRP
Home Nutrition Patients
The acute phase response has no significant effect on the correlation of vitamin E 
with cholesterol in either the ward group of patients or the home nutrition patients 
(Figs 30 and 32). In acutely ill patients in the ICU or HDU (Fig 31) the acute phase 
response has a significant effect on the correlation of cholesterol and vitamin E. 
This is an important observation and replicates the findings by Curran et a P \
The data from tables 20 and 21 suggests that there is no statistical 
difference in any of the parameters measured between the least deprived GP 
subjects category 1 & 2 and the most deprived category 6 & 7. GP subjects of 
deprivation category 1 & 2 have significantly higher levels of cholesterol and 
triglyceride (table 19 & 20) than normal controls and GP subjects of deprivation 
category 6 & 7 have significantly higher levels of triglyceride (table 19 & 21) than 
normal controls. Both of the GP subject groups have higher vitamin E (table 19,20 
&21), vitamin E/cholesterol ratios (table 19,20 &21) and vitamin E/lipid ratios
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(table 19,20 &21) than normal controls. However it should be noted that there 
were significantly more females in the deprivation category 6 & 7 group than the 
other two groups and this may have an effect on the measured parameters.
These findings are at odds with what was expected. As there is a known 
association between deprivation and ischaemic heart disease, it was assumed 
that subjects with deprivation categories 6 & 7 would have increased levels of 
peroxidation and therefore lower levels of vitamin E. On the data from this study 
this appears not to be so and that vitamin E appears to be relatively well 
conserved even in deprived populations.
As previously reported there appears to be no sex difference in vitamin E 
level but there is a well known sex differential in relation to cholesterol.
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3.2 Vitamins A and E in Intensive Care Unit Cardiac Injury Study .
3.2.1 Introduction
Specific biochemical markers the cardiac troponins have recently become 
more generally available to clinical laboratories. These new markers allow the 
determination of myocardial muscle damage. This protein is part of a regulatory 
complex (consisting of two subunits of troponin T, one subunit of troponin 0 and 
one subunit of troponin I) which lies on the tropomyosin strand along the actin 
filiment. The low homology between the skeletal muscle and cardiac isoforms, 
as well as a specific amino acid sequence in the cardiac isoform, has allowed 
the production of monoclonal antibodies to give a specific assay for the 
determination of the cardiac isoform. A serum marker which can reflect minor 
(as well as major) cardiac muscle cell damage provides the opportunity to 
observe the effects on vitamin E in patients who are facing free radial challenge.
Samples for measurement were taken over a six month period when all 
patients admitted to ICU, for any reason, were included. The patients had 
measurements of serum cTnl and were classified on the basis of these results. 
The points chosen for classification were taken from a study of clinical 
interpretation of cTnl results which classified levels from 1000 patients admitted 
to the Victoria Infirmary with acute chest pain^ ^®. This classification is as follows:
• A cTnl level of < 0.04 |iig/L indicates no myocardial injury assuming 
6 hours post cardiac event.
• A cTnl level between 0.04 pg/L and 0.09 pg/L is borderline and may 
suggest developing myocardial injury if < 6 hours post cardiac event or 
the end point of a cardiac event if >120 hours post cardiac event.
• A cTnl level of >0.1 pg/L indicates myocardial tissue injury and a level 
>0.5 jxg/L indicates myocardial damage most probably due to myocardial 
infarction.
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Levels of cTnl may also allow a study of cardiac muscle damage in 
relation to the possible protective effect of vitamin E.
3.2.2 Objectives
To assess levels of vitamin E in a group of critically ill patients, in ICU on 
day one of their stay. This group of patients also had an assessment of 
myocardial muscle injury by measurement of cardiac troponin I.
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3.2.3 Results
Table 22: Demographic Details for ICU Myocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
CTnl levels >0.04 but <0,1 
Borderline
CTnl levels >0.1 
Myocardial Injury
n 48 15 45
Sex (M/F) 27/21 5/10 23/22
Mean Age 59.0 [18.7] 63.3 [22.0] 62.0 [18.8]
Age Range 19 to 85 26 to 99 19 to 89
The results for the Shapiro-Wilk W tests non-normality for all parameters studied in each 
subject group are summarised in table 23.
Table 23: Shapiro-Wilk W Test for Non-normalitv 
ICU Myocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
cTnl levels >0.1 
Myocardial Injury
Vitamin A 0.9648 0.8636 0.9321
p: NS p: 0.0342 p: 0.0124
Vitamin E 0.9560 0.8933 0.9415
p: NS p: NS p: 0.0243
Cholesterol 0.9677 0.8429 0.09135
p: NS p: 0.0138 p: 0.0026
Triglyceride 0.8257 0.8142 0.08212
p: <0.0001 p: 0.0056 p: <0.0001
Vitamin E/ Lipid 0.9788 0.9476 0.09740
Ratio p: NS p: NS p: NS
Vitamin E l 0.9791 0.9641 0.9252
Cholesterol Ratio p:NS p: NS p: 0.0064
Table shows Shapiro-Wilk Coefficient and p value.
A p value < 0.05 indicates significant non-normality of distribution
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The measurements made in plasma in the ICU myocardial injury study are 
presented in table 24 as mean + standard deviation as well as the median + 
interquartile range. The vitamin E/lipid ratio is expressed as pmol of vitamin E per 
mmol of cholesterol and triglyceride in plasma. The vitamin E/cholesterol ratio is 
expressed as pmol of vitamin E per mmol of cholesterol in plasma.
Table 24: Vitamins A & E. Cholesterol and Triglyceride.
ICU Myocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
cTnl levels >0.1 
Myocardial Injury
Vitamin A 1.23 [0.52] 0.78 [0.36] 1.06 [0.67]
(|imol/L) 1.12 [0.72] 0.76 [0.60] 0.97 [0.92]
Vitamin E 20.4 [9.6] 17.3 [9.6] 19.7 [10.7]
(|imol/L) 18.0 [12.2] 16.0 [8.0] 18.0 [13.0]
Cholesterol 3.14 [1.32] 2.30 [0.86] 3.10 [1.67]
(mmol/L) 2.78 [1.88] 2.28 [0.74] 2.62 [2.27]
Triglyceride 1.20 [0.73] 1.10 [0.74] 1.55 [1.11]
(mmol/L) 1.05 [0.74] 0.88 [0.66] 1.18 [0.99]
Vitamin E/ Lipid 4.79 [1.38] 5.01 [1.92] 4.37 [1.42]
Ratio 4.93 [1.85] 4.65 [2.08] 4.48 [1.52]
Vitamin E/ 6.73 [2.10] 7.36 [2.60] 6.62 [2.18]
Cholesterol Ratio 6.75 [2.22] 7.46 [3.36] 6.30 [1.75]
Mean Levels + [Standard Deviation] and Median + [Inter-quartile Range]
Table 25: Serum Cardiac Troponin I Levels. ICU Mvocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
cTnl levels >0.1 
Myocardial Injury
Mean Cardiac 
Troponin 1 
(ng/L)
0.017 [0.012] 0.059 [0.011] 0.808 [1.425]
Cardiac Troponin 1 
(pg/L) Range
0.001 to 0.040 0.05 to 0.087 0.10 to 9.05
Mean Levels + [Standard Deviation]
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Table 26: Statistical Analysis (Mann-Whitnev): Vitamin A
ICU Mvocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.1 
Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
0.0047 si NS
cTnl levels >0.1 
Myocardial Injury
0.0891
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
Subjects with borderline cTnl levels have significantly lower levels of vitamin A 
than in subjects with no myocardial injury.
Table 27: Statistical Analysis (Mann-Whitnev): Vitamin E 
ICU Mvocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.1 
Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
NS NS
cTnl levels >0.1 
Myocardial Injury
NS
NS = Not statistically significant Î  Significantly Higher. si Significantly lower
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Table 28: Statistical Analysis (Mann-Whitnev): Cholesterol
ICU Mvocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.1 
Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
0.0162 i NS
cTnl levels >0.1 
Myocardial Injury
NS
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
Subjects with borderline cTnl levels have significantly lower levels of cholesterol 
than in subjects with no myocardial injury.
Table 29: Statistical Analysis (Mann-Whitnev): Triglyceride 
ICU Mvocardial Injury Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.1 
Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
NS 0.0772
cTnl levels >0.1 
Myocardial Injury
NS
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
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Table 30: Statistical Analysis (Mann-Whitnev).
Vitamin E/Lipid (Cholesterol + Triglycéride) Ratio
ICU Mvocardial Iniurv Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.1 
Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
NS NS
cTnl levels >0.1 
Myocardial Injury
NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
Table 31: Statistical Analysis (Mann-Whitnev): Vitamin E/Cholesterol Ratio
ICU Mvocardial Iniurv Studv
cTnl Levels <0.04 
No Myocardial Injury
cTnl levels >0.1 
Myocardial Injury
cTnl levels >0.04 but <0.1 
Borderline
NS NS
cTnl levels >0.1 
Myocardial Injury
NS
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
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3.2.4 Discussion
ICU Mvocardial Iniurv Studv
This study of vitamin E and lipid levels in patients in intensive care allowed 
an opportunity to examine vitamin E levels in a clinical situation where their 
antioxidant defences are likely to undergo challenge, it has already been shown 
that injury to the myocardium was a feature of these ill patients^ "^ .^ Those 
showing an elevated serum cardiac troponin I could be argued as having the 
greatest stress.
A surprisingly high proportion of patients (42%) had a level of cardiac 
troponin I > 0.1 jug/L in this ICU study population on their first day of admission. 
As the samples analysed were on the patients first day of admission to ICU it 
suggests that the injury had been initiated before admission to the unit. It is 
before ICU stabilisation that these patients may be exposed to the dual insults 
of hypoxia and hypotension. The myocardial injury in the majority of these 
patients may result from causes other that coronary thrombosis^^®. In fact a 
retrospective case-note review found that myocardial infarction had been 
diagnosed in only four cases. Increases in cTni may be a consequence of 
membrane leakage and not a result of damage to the myofibrillar structure or 
cell death. Troponin I exists in a free cytosolic form as well as complexed with 
troponin T and troponin This damage may be initiated by the action of 
oxygen free radicals on the cell membranes^®^’^ ®^ .
The vitamin A levels of the subjects with no evidence of myocardial injury 
(table 24) were similar to those found in general wards (table 8) in the previous 
nutrition study. The borderline group had lower levels of vitamin A (tables 24 & 
26) but similar levels to those found in the ICU subjects (table?) in the nutrition 
study.
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The patients with a borderline level of cTnl have the lowest cholesterol 
levels (tables 24 & 28). These findings may be related to the case mix in this 
study and may not be replicated in another examination. There is no significant 
difference in either the vitamin E/cholesterol ratio or vitamin E/lipid ratio between 
any of the cTnl groups (tables 24,30 & 31). All cTnl groups give similar ratios 
(table 24) to that found for ICU patients in the nutrition study (table 7). These 
findings should be treated with caution as cholesterol may be lowered in acute 
phase response. Unfortunately no GRP data is available for this set of patients. 
However in view of the findings of the previous study it is more than likely that 
these patients also have lowered cholesterol due to the acute phase response.
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Figure 33: Distribution of Vitamin E in ICU Cardiac Injury Study
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Figure 33 shows the distribution of vitamin E levels in the three study groups 
The distribution of patients with no myocardial injury (represented by cTnl levels 
of <0.04 ug/L) are of the same order as patients with myocardial injury 
(represented by cTnl levels of >0.1 ug/L). These data call into question the 
antioxidant action of vitamin E with regard to ischaemic damage caused by 
oxygen free radicals. But it is interesting to note that the potential role of vitamin 
E as an antioxidant has been called into question because there is vitamin E 
accumulated in the atherosclerotic lesion in humans^® .^ It would appear that 
although vitamin E is an important antioxidant, its biological activity appears to 
modulate a variety of cellular functions, such as inhibition of smooth muscle cell 
proliferation^®" ’^^ ®^ or modulation of platelet function^^®, which are not a result of 
its antioxidant activity. Tissues would therefore require an adequate supply of 
vitamin E if it is to be involved in cellular modulation. Low levels of plasma 
vitamin E may be insufficient to allow modulation of cellular processes. It was 
the results of this study, which reinforced the doubts about conventional 
measures of lipid correcting vitamin E in challenged states.
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3.3 Vitamins A and E in Schizophrenia and Tardive Dyskinaesia.
3.3.1 Introduction
If the phospholipid hypothesis, with regard to schizophrenia outlined in 
1.7.2. is correct then increased lipid peroxidation may deplete vitamin E as it is 
the major membrane antioxidant. This may also be the case in Tardive 
Dyskinesa because prolonged medication with neuroleptic drugs may lead to 
increased lipid peroxidation which in turn may lead to low levels of vitamin
3.3.2 Objectives
To measure Vitamins A and E (as well as cholesterol, triglyceride and 
HDL- Cholesterol) in schizophrenic patients with positive and negative symptoms 
to assess any difference in level between these groups and normal control 
subjects. Also to measure Vitamins A and E (as well as cholesterol, triglyceride 
and HDL- Cholesterol) to assess any difference between schizophrenic patients 
with and without symptoms of Tardive Dyskinesia and normal control subjects.
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3.3.3 Results
Table 32: Demographic Details for Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Negative Symptoms
n 39 30 16
Sex (M/F) 21/18 22/8 13/3
Mean Age 37.2 [14.4] 36.1 [8.4] 49.0 [10.3]
Age Range 16 to 65 23 to 58 27 to 56
From the age data there is no significant difference between the controis and the positives but 
there are significant differences between the control group and the negatives (p = 0.0070) and 
between the positives and the negatives (p = 0.0001).
The results for the Shapiro-Wilk W tests non-normality for all parameters studied in each 
subject group are summarised in table 33.
Table 33: Shapiro-Wilk W Test for Non-Normalitv: Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Negative Symptoms
Vitamin A 0.9090 0.9644 0.8821
p: 0.0040 p: NS p; 0.0418
Vitamin E 0.9554 0.9386 0.9442
p: NS p: NS p: NS
Cholesterol 0.9444 0.9765 0.9553
p: 0.0532 p: NS p: NS
Triglyceride 0.7126 0.9422 0.9078
p: <0.0001 p: NS p: NS
Vitamin E/ Lipid 0.9370 0.7320 0.8930
Ratio p: 0.0303 p: <0.0001 p: 0,0621
Vitamin E/ 0.9468 0.7710 0.9342
Choiesterol
Ratio
p: NS p: <0.0001 p: NS
Table shows Shapiro-Wilk Coefficient and p value.
A p value < 0.05 Indicates significant non-normaiity of distribution
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The measurements made in plasma in the schizophrenia patients study 
are presented in table 32 as mean + standard deviation as well as the median + 
interquartile range. The vitamin E/lipid ratio is expressed as pmol of vitamin E per 
mmol of cholesterol and triglyceride in plasma. The vitamin E/cholesterol ratio is 
expressed as pmol of vitamin E per mmol of cholesterol in plasma.
Table 34: Vitamins A & E. Cholesterol and Triglycéride.
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Negative Symptoms
Vitamin A 1.89 [0.48] 1.73 [0.44] 1.96 [0.61]
(jimol/L) 1.67 [0.67] 1.64 [0.46] 1.82 [0.89]
Vitamin E 34.7 [11.1] 33.3 [12.1] 40.8 [10.8]
(|xmoi/L) 33.0 [16.4] 32.0 [12.7] 40.7 [18.7]
Cholesterol 4.66 [1.24] 4.59 [1.04] 5.42 [0.71]
(mmol/L) 4.40 [1.25] 4.72 [1.48] 5.57 [0.74]
Triglyceride 1.34 [0.98] 1.97 [1.01] 2.34 [1.38]
(mmol/L) 1.08 [0.68] 1.76 [1.61] 2.18 [2.49]
Vitamin E/ Lipid 5.83 [1.16] 5.46 [2.88] 5.49 [1.82]
Ratio 5.60 [1.36] 4.80 [1.52] 4.85 [2.60]
Vitamin E l 7.47 [1.58] 7.73 [4.04] 7.62 [2.14]
Cholesterol
Ratio
7.11 [1.73] 6.86 [2.60] 7.80 [3.92]
Mean Levels + [Standard Deviation] and Median + [Inter-quartile Range]
Table 35: Statistical Analysis (Mann-Whitnevk Vitamin A 
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Positive Symptoms
NS
Schizophrenic Patients 
Negative Symptoms
NS NS
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
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Table 36: Statistical Analysis (Mann-Whitnevk Vitamin E
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Positive Symptoms
NS
Schizophrenic Patients 
Negative Symptoms
0.0783 0.0338 T
NS = Not statistically significant T Significantly Higher. i  Significantly lower
Patients with negative symptoms had a significantly higher vitamin E levels 
than patients with positive symptoms.
Table 37: Statistical Analysis (Mann-Whitnev): Cholesterol 
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Positive Symptoms
NS
Schizophrenic Patients 
Negative Symptoms
0.0054 Î 0.0065 Î
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
Patients with negative symptoms had borderline significantly higher cholesterol 
levels than either the normal controls or the patients with positive symptoms.
Table 38: Statistical Analysis (Mann-Whitnev): Triglyceride 
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Positive Symptoms
0.0016 Î
Schizophrenic Patients 
Negative Symptoms
0.0054 Î NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
Both types of schizophrenic patient had significantly higher levels of triglyceride 
than the normal control group.
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Table 39: Statistical Analysis (Mann-Whitnev)
Vitamin El Lipid (Cholesterol + Triglycéride) Ratio:
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Positive Symptoms
0.0040 si
Schizophrenic Patients 
Negative Symptoms
NS NS
NS = Not statistically significant T Significantly Higher. si Significantly lower
Only the schizophrenic patients with positive symptoms had a significantly lower 
vitamin E/lipid ratio than the normal control group
Table 40: Statistical Analysis (Mann-Whitnev): Vitamin El Cholesterol Ratio
Schizophrenia Patients Studv
Normal Controls Schizophrenic Patients 
Positive Symptoms
Schizophrenic Patients 
Positive Symptoms
NS
Schizophrenic Patients 
Negative Symptoms
NS NS
NS = Not statistically significant Î  Significantly Higher. si Significantly lower
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Table 41: Demographic Details for Tardive Dyskinesia Studv
Normal Controls Schizophrenic Patients 
Tardive Dyskinesia
Schizophrenic Patients 
Controls
n 10 16 16
Sex (M/F) 5/5 5/11 2/14
Mean Age 53.3 [11.5] 63.4 [11.1] 60.4 [12.1]
Age Range 22 to 64 34 to 87 35 to 84
From the age data there is a significant difference between the normal controls and both the 
Schizophrenic Control group (p: <0.05) and the Tardive Dyskinesia Group (p: <0.05).
Table 41a: Shapiro-Wilk W Test for Non-Normalitv: Tardive Dyskinesia Studv
Normal Controls Schizophrenic Patients 
Tardive Dyskinesia
Schizophrenic Patients 
Controls
Vitamin A 0.9291 0.8983 0.9326
p: NS p: NS p: NS
Vitamin E 0.9553 0.8267 0.9591
p: NS p: NS p: NS
Cholesterol 0.7913 0.9556 0.9346
p: 0.0114 p: NS p: NS
Triglyceride 0.9107 0.8285 0.8790
p: NS p: 0.0067 p: 0.0459
Vitamin E/ Lipid 0.9099 0.9290 0.8930
Ratio p: NS p: NS p: 0.0621
Vitamin E/ 0.8966 0.9788 0.9321
Cholesterol
Ratio
p: NS p: NS p: NS
Table shows Shapiro-Wilk Coefficient and p value.
A p value < 0.05 indicates significant non-normality of distribution
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Table 42: Vitamins A & E. Cholesterol and Triglyceride.
Tardive Dyskinesia Studv
Normal Controls Schizophrenic Patients 
Tardive Dyskinesia
Schizophrenic Patients 
Controls
Vitamin A 2.70 [0.60] 2.50 [0.93] 2.17 [0.50]
(pmol/L) 2.86 [0.88] 2.34 [1.02] 2.11 [0.76]
Vitamin E 35.8 [7.4] 26.6 [11.2] 26.2 [6.1]
(pmol/L) 36.2 [7.2] 24.0 [12.2] 26.0 [9.3]
Cholesterol 5.74 [0.81] 4.84 [1.29] 4.71 [0.95]
(mmol/L) 6.17 [1.24] 4.77 [1.84] 4.62 [1.42]
Triglyceride 2.25 [1.07] 2.23 [1.32] 1.46 [0.72]
(mmol/L) 1.99 [1.09] 1.85 [1.69] 1.44 [0.78]*
HDL-Cholesterol 1.27 [0.35] 0.97 [0.17] 1.10 [0.14]
(mmol/L) 1.28 [0.44] 0.97 [0.23] 1.12 [0.14]*
Vitamin E/ Lipid 4.50 [0.92] 3.74 [0.62] 4.44 [0.91]
Ratio 4.23 [0.98] 3.94 [1.03] 4.12 [1.54]*
Vitamin E/ 6.22 [0.96] 5.42 [1.17] 5.76 [1.15]
Cholesterol Ratio 6.54 [1.19] 5.62 [1.83] 5.88 [2.08]*
Mean Levels + [Standard Deviation] and Median + [Inter-quartile Range]
Although the majority of analytes for the above subject groups showed a normal distribution 
(Table 41a) median and Interquartile Ranges are shown for consistency.
* One patient was omitted from the schizophrenic control group as the triglyceride was >3SD 
from the mean and was therefore regarded as an outlier.
Table 43: Statistical Analysis (Independent Samples t-test): Vitamin A
Tardive Dyskinesia Studv
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
0.0108 i
Schizophrenic Patients 
Tardive Dyskinesia
NS NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
Schizophrenic controls had significantly lower vitamin A levels than the normal control group
Page 135
Table 44: Statistical Analysis (Independent Samples t-test): Vitamin E
Tardive Dyskinesia Study
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
0.0026 i
Schizophrenic Patients 
Tardive Dyskinesia
0.0309 i NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
Both the schizophrenic controls and Tardive Dyskinesia patients has significantly lower 
levels of vitamin E than the control group.
Table 45: Statistical Analysis (Independent Samples t-test): Cholesterol 
Tardive Dyskinesia Study
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
0.0095 i
Schizophrenic Patients 
Tardive Dyskinesia
0.0591 NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
The schizophrenic control group had significantly lower levels of cholesterol 
than the normal control group.
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Table 46: Statistical Analysis (Independent Samples t-test): Triglyceride
Tardive Dyskinesia Study
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
0.0379 i
Schizophrenic Patients 
Tardive Dyskinesia
NS 0.0558
NS = Not statistically significant T Significantly Higher. i  Significantly lower
The schizophrenic control group had significantly lower levels of triglyceride 
than the normal control group.
Table 47: Statistical Analysis (Independent Samples t-test) 
HDL-Cholesterol. Tardive Dyskinesia Study
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
NS
Schizophrenic Patients 
Tardive Dyskinesia
0.0062 i 0.0264 i
NS = Not statistically significant T Significantly Higher. i  Significantly lower
The Tardive Dyskinesia patient group had significantly lower levels of HDL-cholesterol 
than the normal control group and the schizophrenic control group.
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Table 48: Statistical Analysis (Independent Samples t-test)
Vitamin E/ Lipid (Cholesterol + Triglyceride) Ratio
Tardive Dyskinesia Study
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
NS
Schizophrenic Patients 
Tardive Dyskinesia
0.0182 i 0.0159 i
NS = Not statistically significant Î  Significantly Higher. i  Significantly lower
The Tardive Dyskinesia patient group had significantly lower levels of vitamin E/lipid ratio 
than the normal control group and the schizophrenic control group.
Table 49: Statistical Analysis (Independent Samples t-test) 
Vitamin El Cholesterol Ratio. Tardive Dyskinesia Study
Normal Controls Schizophrenic Patients 
Controls
Schizophrenic Patients 
Controls
NS
Schizophrenic Patients 
Tardive Dyskinesia
0.0831 NS
NS = Not statistically significant T Significantly Higher. i  Significantly lower
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3.3.4: Discussion
Schizophrenic Patients with positive or negative symptoms
Tables 32 to 40 show the demographic, descriptive and statistical analysis 
carried out for the subject groups in the study. The schizophrenic groups had 
significantly more males than females with the negative group significantly older 
than the other two groups. There was no difference in the vitamin A levels (table 
34 & 35) of the subject groups suggesting adequacy of intake.
□  Controls
■  Schizophrenic (Positives)
□  Schizophrenic (Negatives)
[Vitamin E]p.mol/L
Figure 34: Distribution of Vitamin E levels in Schizophrenic Patients Study
Figure 34 shows the distribution of vitamin E levels in all subjects in this 
study. It clearly shows no subjects within these three groups had a vitamin E 
level indicating deficiency. In fact both schizophrenic groups showed 
distributions which were skewed to higher vitamin E levels than the control 
group. Patients with negative symptoms showed higher levels of vitamin E 
(tables 34 & 36), and cholesterol (tables 34 & 37) when compared with the
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positive symptoms group. The negative symptoms group also showed higher 
levels of cholesterol (tables 34 & 37) and triglyceride (tables 34 & 38) than the 
normal control group. The positive group showed higher levels of triglyceride 
(table 34 & 38) when compared to the normal controls and was the only group to 
show a lower level of vitamin E/lipid ratio (tables 34 & 39). However, neither the 
positive group nor the negative group showed any statistical difference with the 
normal control group when analysing the vitamin E/cholesterol data (table 40). 
The lower vitamin E/lipid ratio in the positive symptom group is due to the action 
of triglyceride, which is higher in this group. The data provides no supporting 
evidence that vitamin E depletion is a feature of these patients. There are, 
however, differences between schizophrenic patients with positive and negative 
symptoms with respect to plasma vitamin E levels
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Tardive Dyskinesia Patients.
The schizophrenic patients from this study showed a predominance 
of female subjects. The schizophrenic groups were also statistically older 
(table 41). There was no significant difference between the schizophrenic subject 
groups with regard to vitamin A suggesting adequacy of intake in those two 
groups. However the schizophrenic control group did have significantly lower 
levels than the normal control group (tables 42 & 43).
Vitamin E levels were statistically significantly lower in both schizophrenic 
groups compared to normal controls (tables 42 & 44). Although it visually 
appears in figure 35 that the tardive dyskinesia group is not normally distributed 
non-parametric statistical measures, Mann-Whitney, confirm these findings 
(normal controls vs tardive dyskinesia group (p: 0.131) and normal controls vs 
schizophrenic controls (p: 0.0044)). However figure 35 shows no group with a 
vitamin E level indicating deficiency.
In
0
1E
6
5
□  Controls
□  Schizophrenic Controls 
■  Tardive Dyskinesa
3
2
1
0
[Vitamin E] pmol/L
Figure 35: Distribution of Vitamin E levels in Tardive Dyskinesa Study
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The cholesterol and triglyceride levels were lower in the schizophrenic 
control group compared to normal controls (tables 42, 45 & 46). The HDL- 
cholesterol level was lower in the tardive dyskinesia group compared to both the 
normal controls and the schizophrenic controls (tables 42 & 47) and may be due 
to lack of exercise and high levels of smoking^®  ^in this patient group. The 
vitamin E lipid ratio levels showed significantly lower levels in the schizophrenic 
tardive dyskinesia group compared to the control group also a lower level was 
found in the tardive dyskinesia group compared to the schizophrenic control 
group (tables 42 & 48).
A chronic and sustained deficiency of vitamin E could conceivably render 
subjects more susceptible to free radical damage, lipid membrane peroxidation 
and ultimately tardive dyskinesia. However there is a serious caution to this 
conclusion as the vitamin E/cholesterol ratio shows no difference between the 
three groups (tables 42 & 49). These data may be due to the effect of triglyceride 
on the vitamin E lipid ratio with the tardive dyskinesia group having triglycerides 
levels similar to the normal controls but higher than the schizophrenic controls. 
Some of these data have been published (Brown K, Reid A, et al 1998)^ ®®. This 
study has limitations the most important being sample size. In addition, the 
schizophrenic subjects enrolled into the study were atypical in that they were 
mostly old and chronically institutionalised.
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4 General Discussion
In the introduction to this thesis free radical damage, particularly lipid 
peroxidation, and the use of antioxidants to prevent disease states associated 
with radical damage was discussed. On reading the literature there is an 
assumption that antioxidants, such as vitamin E, will be depleted to such an 
extent as to cause deficiency or low levels of vitamin which are insufficient to 
defend against radical attack and therefore radical production can then initiate 
disease processes. The data from studies carried out in this thesis have not 
added support to this view although the selection of subjects with more severe 
abnormalities may have shown an effect.
The highest percentage of subjects with vitamin A levels below 0.7 jimol/L 
were found in the ICU and HDU subjects (table 50). This finding is not surprising 
as these patients probably have low levels of retinol binding protein due to the 
acute phase and in some cases liver disease. This may also have implications in 
studies of vitamin E.
Table 50: Number and Percentage of Nutrition Studv Patients with 
Vitamin A levels less than 0.7 nmol/ L
Nutrition
Study
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
Vitamin A 
<0.7 |imol/L
114 33 84 1 2
Total 540 70 186 171
Percentage 21.1% 47.1% 45.2% 1.2%
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No level of vitamin E below 13 pmol/L (lower limit of the calculated normal range, 
page 88) was found in normal control subjects, general practice subjects or either 
of the schizophrenic study subjects. Figure 35a shows the distribution of vitamin E 
levels in all study groups and table 51 indicates the percentage of subjects with 
vitamin E levels below lower limit of the normal range.
120
100
□  Ward
■  HDU
■  ICU
□  NUT
■  ICU Cardiac
□  TD Study
■  Schizophrenia Study
□  Normals
■  GP Study
[Vitamin E] p,mol/L
Figure 35a: Distribution of Vitamin E levels in all Studies
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Table 51: Number and Percentage of Nutrition Studv Patients below the
lower limit of normal for Vitamin E
Nutrition
Study
Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
Vitamin E 
<13 pmoi/L
45 13 62 21
Total 540 70 186 171
Percentage 8.3% 18.6% 33.3% 12.2%
As expected the largest percentage of subjects with low vitamin E levels can be 
found the ICU ward. However, previous publications''®®’''^ ® have suggested that 
vitamin E should not be conventionally treated in isolation and should be related 
to lipid either as a ratio of cholesterol or of cholesterol + triglyceride. Table 52 and 
53 indicate the percentage of subjects with their vitamin E/cholesterol and vitamin 
E/ lipid ratios below the lower limit of normal.
Table 52: Number and Percentage of Nutrition Studv Patients below the 
lower limit of normal for Vitamin E/Lipid Ratio
Patients Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
Vitamin E/lipid 
Ratio <2.4
12 2 16 11
Total 540 70 186 171
Percentage 2.2% 2.8% 8.6% 6.4%
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Table 53: Number and Percentage of Nutrition Studv Patients below the
lower limit of normal for Vitamin E/Cholesterol Ratio
Patients Ward High
Dependency
Unit
Intensive 
Care Unit
Home
Nutrition
Patients
Vitamin E/cholesterol 
Ratio <3.01
14 1 4 7
Total 540 70 186 171
Percentage 2.6% 1.4% 2.2% 4.1%
There is substantial literature indicating that patients in intensive care are 
stressed by free radical damage and yet the observations reported in the studies 
of intensive care patients shows that subnormal levels of vitamin E, expressed as 
either vitamin E/lipid ratio (table 52) or vitamin E/cholesterol ratio (table 53), were 
unusual. This apparent contradiction has resulted in a reconsideration of the 
correction of vitamin E with lipid in acutely ill patients.
From a whole body point of view it is essential that the dietary source of 
vitamin E absorbed and transported to the liver is adequately distributed to the 
point of need, where membrane free radical activity is required to be countered. 
Although, as seen in figures 36 -  44, there is generally a good correlation 
between cholesterol and vitamin E this correlation should be treated with caution 
in the acutely ill patient where a low cholesterol may be due to the effects of the 
acute phase (figure 31) and the amount of vitamin E transported in the blood is 
low. Sequestered vitamin E as occurs in the acute phase^^ may not be adequate 
for tissue need if the oxidative stress is prolonged. In the schizophrenic subjects 
who’s disease state is chronic, correlation between vitamin E and cholesterol 
(figures 44 & 45) is poor and may indicate a different mechanism is operating in 
this condition.
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Figure 36; Normal Control Vitamin E vs Cholesterol Correlation r; 0.73 p: <0.0001
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Figure 37: Ward Vitamin E vs Cholesterol Correlation r; 0.52 p: <0.0001
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Figure 39: HDU Vitamin E vs Cholesterol Correlation r; 0.53 p: <0.0001
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Figure 40: ICU Vitamin E vs Cholesterol Correlation r; 0.73 p: <0.0001
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Figure 41; GP Study Vitamin E vs Cholesterol Correlation r; 0.73 p: <0.0001
100 n
90 - 
80 -
E 60 H
uj" 50 - c
re 40 ■ 
^  30 - 
20 ■ 
10 ■
0
0 2 4 6
[Cholesterol] mmol/L
Figure 42: Home Nutrition Patients Vitamin E vs Cholesterol Correlation
r: 0.58 p: <0.0001
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Figure 43: ICU Cardiac Injury Study Vitamin E vs. Cholesterol Correlation 
cTnl (<0.04 ug/L) r; 0.72 p; <0.0001. cTnl(>0.4 <0.1 ug/L) r; 0.77 p; <0.0001 
cTnl (>0.1 ug/L) r; 0.84 p; <0.0001
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Figure 44: Tardive Dyskinesa Study: Vitamin E vs. Cholesterol Correlation 
Controls: r; 0.70, p;0.0248. Tardive Dyskinesa Group: r; 0.85, p; <0.0001. 
Schizophrenic Control Group: r; 0.58, p; 0.0243.
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Figure 45: Schizophrenia Patient Study: Vitamin E vs. Cholesterol Correlation 
Controls: r; 0.76, p:<0.0001. Negatives: r; 0.16, p; 0.5565.
Positives: r; 0.05, p; 0.8061
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As previously discussed in 1.5.2 the mechanism of vitamin E absorption is 
unclear. All forms of vitamin E are taken up by intestinal cells and released into 
the circulation with chylomicrons where they reach the liver via chylomicron 
remnants. In the liver, a specific protein, a-Tocopherol Transport Protein (a- 
TTP) selectively sorts a-tocopherol for incorporation into VLDL and hence LDL 
via IDL. The capacity of plasma to increase vitamin E concentration is limited 
and is apparently not due to limited absorption . In addition, newly absorbed 
vitamin E (in the form of a-tocopherol) replaces old vitamin E in plasma 
lipoproteins which may be the limiting step in overall incorporation . The 
underlying reasons are unclear but may include variations in a-TTP activity, 
metabolic rate, lipid content and composition, the status of other micronutrients 
that recycle vitamin E and environmental conditions. It seems likely that an 
adequate or optimal supply can vary between individuals. The results from the 
studies carried out in this thesis suggest, with the exception of some subjects in 
ICU and HDU, most are likely to have adequate absorption and transport of 
vitamin E evidenced by their normal plasma vitamin E levels (figure 35a). 
Subjects from ICU have greatest percentage (33.3%) of vitamin E levels 
< 13 pmol/L with HDU subjects and ward subjects showing percentages of 
18.6% and 8.3% respectively. This suggests that the levels of vitamin E of these 
subjects may be insufficient to allow protection of the lipids in cell membranes 
against peroxidation or to enable possible secondary modulation actions such 
as anti-inflammatory effects or inhibition of platelet aggregation as previously 
discussed. It should be noted that the subjects in ICU (Table 7 and Table 24) 
and HDU (Table 7) show the lowest cholesterol levels of all the groups studied. 
This may be due in part to the effects of the acute phase (figure 31) on 
cholesterol levels but also possibly decreased absorption and liver transport.
A low vitamin E may indicate deficiency but not its cause. However depending 
on the cholesterol and CRP levels (indicates acute phase response) some 
indication may be given to the cause of low vitamin E levels. For example a low
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cholesterol with a low vitamin E could in the absence of an elevated CRP 
indicate decreased absorption and normal cholesterol with a low vitamin E may 
indicate impaired liver transport. It seems obvious that the subjects in ICU and 
HDU are at greatest risk as they are unable to absorb, transport and deliver to 
tissue membranes the vitamin E required to directly neutralise the damage to 
membranes lipids by free radicals or modulate secondary responses which may 
lead to the initiation of cellular defences to radical attack. Whether these 
patients would benefit from supplementation is open to debate as the newly 
absorbed vitamin E would only replace the old vitamin E in plasma lipoproteins 
and there may be variation in a-TTP activity. There is a requirement to measure 
patients’ lipid levels, acute phase reactants such as CRP and liver function to 
assess the capacity to transport vitamin E.
In the schizophrenia studies the subjects with positive and negative 
symptoms show no correlation between cholesterol and vitamin E (Figure 45) 
and are in fact the only two groups to do so. This lack of correlation may be due 
to dietary effects or subjects taking vitamin E supplements. It should be noted 
that these studies are limited because of the number and demographic makeup 
of the subjects. Although vitamin E cholesterol ratios in the schizophrenia study 
and the tardive dyskinesia study show no significant difference between their 
respective study control groups and the schizophrenia patient subjects, there 
are significant differences with regard to vitamin E. The negative schizophrenics 
gave a statistically significantly lower vitamin E in relation to the positive 
schizophrenic group but not the normal control group. Both the schizophrenic 
control and tardive dyskinesia groups show a statistically significantly lower 
vitamin E than their normal control group. These findings in schizophrenic 
groups may be due to disease process, dietary effects or possibly deficiencies 
in liver a-TTP activity.
It was postulated that the patients in the ICU cardiac injury study would be 
under greater free radical insult and therefore show lower vitamin E levels in
Page 153
patients with troponin I levels indicating cardiac muscle injury. Although some 
subjects had low vitamin E this was also the finding for the study group with no 
evidence of cardiac muscle injury. It therefore appears from these data that there 
is no relationship between vitamin E and cardiac injury.
The findings of a close correlation between vitamin E and cholesterol 
suggests that in non-acutely ill patients a corrected vitamin E cholesterol ratio 
may be used as an indicator of absorption and transport via liver a-Tocopherol 
Transport Protein into the plasma. Adequate levels may indicate the availability of 
vitamin E to the tissues. It is inappropriate to correct for lipid in the acutely ill 
patient due to the unpredictable effects on absorption, liver a-Tocopherol 
Transport Protein activity and lipoprotein content. For these subjects vitamin E 
should not be corrected for lipid but should also not be treated in isolation. Due 
regard to should be paid to effects of the acute phase response, decreased 
absorption and liver disturbance.
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Conclusion
Low levels of vitamin A are relatively common in the hospital population. However 
plasma vitamin A level interpretation may be complicated by the effects on retinol 
binding protein by co-existing liver disease and acute phased response. It may 
be more appropriate to measure vitamin A in tissues, such as erythrocytes, that 
may not be affected by the acute phase response.
A low plasma vitamin E is a rare occurrence in the general population, 
however it is found more commonly in the hospital in-patient population. The 
concept of correcting vitamin E with lipid is appropriate when dealing with 
subjects in the general population but should not be used when assessing 
nutritionally depleted in-patients or in subjects who have low cholesterol levels 
and evidence of acute phase response. Tissue vitamin E measurements may 
provide the only reliable means of indicating deficiency.
Further larger studies on schizophrenia and tardive dyskinesia subjects 
are required to confirm the findings of this thesis. The definition of patients with 
positive and negative symptoms of schizophrenia is less well recognised now 
than when these studies were completed and will require review when the causes 
of positive and negative symptoms become clearer.
There are currently many studies looking into the effects of vitamin E 
supplementation and ischaemic heart disease which have still to report. However 
the MRC/BHF Heart protection study has reported no benefit in vitamin E 
supplementation. It is interesting that the ICU myocardial injury study showed no 
significant difference in the vitamin E levels in patients with myocardial injury 
indicated by cardiac troponin I levels. There is some thought that vitamin E, as an 
antioxidant, is not directly responsible for the protective effects associated with 
ischaemic heart disease but that it modulates cellular functions^®^’
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Using direct measurements of lipoprotein fractions and oxidised LDL would 
have been more appropriate in helping assess deficiency of the fat soluble 
vitamins investigated in this thesis. It may be appropriate to examine other 
components such as cytosolic phospholipase
5-lipoxygenase^^^ as it has been shown to regulate the expression of these 
enzymes.
Although the title of this thesis indicates a study of a wide range of 
determinants of free radical activity the work has concentrated on vitamin E. In 
this thesis vitamin E measurement either alone or with lipid correction have been 
examined in a wide range of clinical situations. The use of lipid correction for 
vitamin E measurement should be used with caution. For the majority clinical 
applications the most reliable and available assessment of the vitamin is the 
plasma measurement without lipid correction.
As new hypotheses of vitamin E actions on the modulation of cellular 
function are investigated an indication of a patients vitamin E level will be still be 
required. The last word on actions of vitamin E is still yet to be written.
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Appendix 1
Suppliers of Reagents, Equipment and Software 
Alpha Laboratories Limited
40 Parham Drive, Eastleigh, Hampshire SO50 4NU
Capped Eppendorph tubes 
Anachem Limited
Anachem House, Charles Street, Luton, Bedfordshire LU2 DEB
Gilson Micro Volume Pipettes
P100 Volume range: 2 0 -  100 pi
P200 Volume range: 50 -  200 pi
P I000 Volume range: 200 -  1000 pi
Analyse-lt Software Ltd
PO Box 77, Leeds LSI2 5XA
Analyse-it software a statistical analysis add in for Microsoft® Excel®. 
Agilent Technologies UK Limited
Chemical Analysis Group, Lakeside, Cheadle Royal Business Park 
Stockport, Cheshire SK8 3GR.
High Performance Liquid Chromatography 1100 Series 
Chemstation Control and Integration Software
Beckman Coulter UK Limited
Oakley Court, Kingsmead Business Park, London Road,
High Wycombe, Buckinghamshire HP11 1JU.
Access Immunoassay System.
Cardiac Troponin I Reagent Pack, Cat. No.: 33320.
Cardiac Troponin I Calibrators, Cat. No.: 33325.
Cardiac Troponin I Quality Control Cat. No.: 33329.
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BDH Laboratory Supplies
McQuilkin & Co., 21 Polmadie Avenue, Glasgow G5 OBB 
HPLC Grade Acetonitrile, Methanol, Water and Hexane 
Bio-Rad Laboratories Limited
Bio-Rad House, Maylands Avenue, Hemel Hempstead, Herts, HP2 7TD. 
Lyphocheck Immunoassy control 1 and 3 for vitamin internal Quality control. 
Bio-Stat Diagnostics Systems
Biostat House, Pepper Road, Hazel Grove, Stockport, Cheshire SK7 5BW.
HDL-Cholesterol Kit Cat. No.: 915090.
Bio-Stat HDL-Cholesterol Calibrator, Cat. No.: 915084.
British Oxygen Company
BOC Gases and Gear Centre, 150 Polmadie Road, Glasgow 
Oxygen Free Nitrogen.
Crawford Scientific
Holm Street, Strathaven, Lanarkshire ML10 6NB
5 ml Amber Vials and screw caps.
300 pi Glass Inserts for amber vials.
Butyl rubber seals
Diagnostic Scotland
Law Hospital, Carluke, ML8 5QZ
Low, Mid and High Quality Control Material.
DakoCytomation Ltd
Denmark House, Angle Drove, Ely, Cambs CB7 4ET
Rabbit Anti-human CRP antibody 
CRP Assay Reaction Buffer 
CRP Diluent Buffer
Hayman Ltd
Eastways Park, Witham, Essex CM8 3YE.
Ethanol
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Microsoft® Corporation
One Microsoft Way, Redmond, WA 98052-6399 USA
Microsoft® Word® 2000 
Microsoft® Excel® 2000
PerkinElmer Life Sciences
PerkinElmer House
204 Cambridge Science Park, Milton Road, Cambridge CB4 OGZ 
Lamda 5 UV/VIS scanning spectrophotomer.
Phenomenex
Queens Avenue, Hurdsfield Industrial Estate, Macclesfield, Cheshire SK10 2BN
Ultracarb 5p ODS(20) 150 x 3.2 mm HPLC Column.
Ultracarb 5p ODS(20) 30 x 4.3 mm HPLC guard Column.
Protein Reference Unit
Department of Immunology, PO Box 894, Sheffield S5 7YT.
C-reactive protein calibrant SPS-03 
SPS-12 and SPS-13 control material
Roche Diagnostics Limited
Bell Lane, Lewes, East Sussex BN7 1LG
Hitachi 717 automatic analyser
Cholesterol Kit Cat. No.: 1489437
Cholesterol Standard, P reel path L, Cat. No.: 1285874.
Triglyceride Kit Cat. No.: 1488899
Trigiyceride Standard, Precipath L, Cat. No.: 1285874
Sigma Chemical Company
Fancy Road, Pooie Dorset BH17 7NH
Retinol (Cat. No. 95144)
Retinol Acetate (Cat. No. 46958) 
a-tocopherol (Cat. No. T3257) 
tocopherol acetate (Cat. No.T3001)
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Techne (Cambridge) Limited
Duxford Road, Cambridge, England
Techne Dri-Block DB3 with SC3 Sample Concentrator. 
Thistle Scientific Limited
DFDS House, Goldie Road, Uddingston, Glasgow G71 6NZ 
MSB Microcentrifuge
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Glossary
A
OH*
" : 0 :
2
AMI 
ADP
a-TTP
ATP
ACAT
APO Cll
APOB
CRP
CT
cTnl
DMA 
DNA 
EAR
GSH
GSH-PX
HALS
HAMA
HDL
HMG-CoA Reductase
HPLC
IDL
Ascorbyl radical
Hydroxyl Radical 
Hydrogen Peroxide
Singlet molecular oxygen
Superoxide radical
Acute myocardial infarction 
Adenosine Diphosphate 
a-tocopherol transfer protein 
Adenosine Triphosphate 
Acyl-cholesterol acyltransferase 
Apolipoprotein Cll 
Apolipoprotein B 
C- Reactive Protein 
Catalase
Cardiac troponin I 
Dehydroascorbic acid 
Deoxyribonucleic acid 
Estimated Average Daily Requirement 
Glutathione (Reduced)
Glutathione peroxidase
4-hydroxyl alkanals
Human anti-mouse antibodies
High Density Lipoprotein
3-hydroxy-3-methylglutaryl-CoA Reductase
High pressure liquid chromatography
Intermediate density lipoprotein
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LDL Low Density Lipoprotein
LPO Lipid peroxidation
MCP-1 Monocyte chemotactic protein-1
M-CSF Macrophage colony stimulating factor
mm-LDL minimally modified Low Density Lipoprotein
NAD Nicotinamide Adenine Dinucleotide
NADH Dihydronicotinamide Adenine Dinucleotide
NADP Nicotinamide Adenine Dinucleotide Phosphate
NADPH Dihydronicotinamide Adenine Dinucleotide Phosphate
ox-LDL Oxidised Low Density Lipoprotein
PAI-1 Plasminogen activator inhibitor-1
PET Positron Emission Tomography
PLAz Phospholipase A2
Partial Pressure of Oxygen
PU FA Polyunsaturated fatty acids
RBC Red blood cell
RDA Recommended Daily Allowance
ROS Reactive oxygen species
RNI Reference Nutrient Intake
SMR Standardised mortality ratio
SOD Superoxide dismutase
TBARS Thiobarbituric acid reactive substances
TD Tardive Dyskinesia
TF Tissue factor
TG Triglyceride
UV Ultra Violet
VIS Visible
VLDL Very Low Density Lipoprotein
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